

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07D 333/74, 333/56, 333/22, 277/04, 277/18, A61K 31/38, 31/425</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/62897</b>
		<b>(43) International Publication Date:</b> 9 December 1999 (09.12.99)	
<b>(21) International Application Number:</b> PCT/US99/12094		<b>(81) Designated States:</b> AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
<b>(22) International Filing Date:</b> 1 June 1999 (01.06.99)			
<b>(30) Priority Data:</b> 60/087,846 3 June 1998 (03.06.98) US 9814925.5 9 July 1998 (09.07.98) GB			
<b>(71) Applicant (for all designated States except US):</b> MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			
<b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> YOUNG, Steven, D. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). WAI, John, S. [-/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). EMBREY, Mark, W. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). FISHER, Thorsten, E. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			
<b>(74) Common Representative:</b> MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		<b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> HIV INTEGRASE INHIBITORS			
<b>(57) Abstract</b> <p>Sulfur-containing heteroaryl dioxo-butyric acid derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF THE INVENTION  
HIV INTEGRASE INHIBITORS

CROSS-REFERENCE TO RELATED APPLICATIONS

- 5                   The present application claims priority of U.S. provisional application Serial No. 60/087,846, filed June 3, 1998.

BACKGROUND OF THE INVENTION

- 10                   A retrovirus designated human immunodeficiency virus (HIV) is the etiological agent of the complex disease that includes progressive destruction of the immune system (acquired immune deficiency syndrome; AIDS) and degeneration of the central and peripheral nervous system. This virus was previously known as LAV, HTLV-III, or ARV. A common feature of retrovirus  
15                   replication is the insertion by virally-encoded integrase of proviral DNA into the host cell genome, a required step in HIV replication in human T-lymphoid and monocytoid cells. Integration is believed to be mediated by integrase in three steps: assembly of a stable nucleoprotein complex with viral DNA sequences; cleavage of two  
20                   nucleotides from the 3' termini of the linear proviral DNA; covalent joining of the recessed 3' OH termini of the proviral DNA at a staggered cut made at the host target site. The fourth step in the process, repair synthesis of the resultant gap, may be accomplished by cellular enzymes.

- 25                   Nucleotide sequencing of HIV shows the presence of a pol gene in one open reading frame [Ratner, L. et al., Nature, 313, 277(1985)]. Amino acid sequence homology provides evidence that the pol sequence encodes reverse transcriptase, integrase and an HIV protease [Toh, H. et al., EMBO J. 4, 1267 (1985); Power, M.D. et al.,  
30                   Science, 231, 1567 (1986); Pearl, L.H. et al., Nature, 329, 351 (1987)]. All three enzymes have been shown to be essential for the replication of HIV.

- It is known that some antiviral compounds which act as inhibitors of HIV replication are effective agents in the treatment of  
35                   AIDS and similar diseases, e.g., azidothymidine or AZT. Applicants

demonstrate that the compounds of this invention are inhibitors of HIV integrase and inhibitors of HIV replication. The applicants additionally demonstrate that inhibition of integrase in vitro and HIV replication in cells is a direct result of inhibiting the strand transfer reaction catalyzed by the recombinant integrase in vitro and integrase as a component of the preintegration complex in HIV infected cells. The particular advantage of the present invention is highly specific inhibition of HIV integrase and HIV replication. The compounds of the present invention inhibit integrases of closely related lentiviruses such as HIV 2 and SIV, but not integrases from more distantly related retroviruses, for example RSV. These compounds do not inhibit binding or catalysis of other nucleic acid binding proteins, including enzymatic reactions such as those catalyzed by HIV reverse transcriptase, HIV RNase H, Influenza transcriptase, Hepatitis C polymerase, Yeast DNA polymerase, DNase I, Eco RI endonuclease, or mammalian polymerase II.

Zhao et al., (J. Med. Chem. vol. 40, pp. 937-941 and 1186-1194 (1997)) describe hydrazide and arylamide HIV integrase inhibitors. Bis-catechols useful for inhibiting HIV integrase are described in LaFemina et al. (Antimicrobial Agents & Chemotherapy, vol. 39, no. 2, pp. 320-324, February 1995).

U.S. Patents 4,377,258; 4,336,397; and 4,423,063 as well as Williams and Rooney (J. Med. Chem. vol 26, pp. 1196-1200, 1983) disclose 2,4-dioxo-4-substituted-1-butanoic acid derivatives useful in treating urinary tract calcium oxalate lithiasis. 4-substituted 2,4-dioxobutanoic acid compounds useful for inhibiting an influenza virus endonuclease are described in Tomassini et al. (Antimicrobial Agents & Chemotherapy, vol. 38, no. 12, pp. 2827-2837, December, 1994).

Applicants have discovered that certain 5-membered sulfur containing heteroaromatic diketo acid derivatives are potent inhibitors of HIV integrase. These compounds are useful in the treatment of AIDS or HIV infection.

## SUMMARY OF THE INVENTION


Compounds of formula I, as herein defined, are disclosed. These compounds are useful in the inhibition of HIV integrase, the prevention of infection by HIV, the treatment of infection by HIV and in the treatment of AIDS and/or ARC, either as compounds,

- 5 pharmaceutically acceptable salts or hydrates (when appropriate), pharmaceutical composition ingredients, whether or not in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS, methods of preventing infection by HIV, and methods of treating infection by HIV are also disclosed.

10


### DETAILED DESCRIPTION OF THE INVENTION

- This invention is concerned with compounds of formula I, combinations thereof, or pharmaceutically acceptable salts thereof, in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and in the treatment of the resulting acquired immune deficiency syndrome (AIDS). Compounds of formula I are defined as follows:



- and tautomers or pharmaceutically acceptable salts thereof, wherein:

A is a five-membered heteroaromatic ring containing 1 sulfur atom and 0 or 1 nitrogen atoms and substituted on carbon by  $R^1$ ,  $R^2$  and  $R^8$ ; the heteroaromatic ring may optionally be fused with a phenyl ring or a C<sub>4-6</sub> cycloalkyl ring, or with two six membered rings to form:



25

$R^1$  is selected from:

- (1) -H,
- (2) -C<sub>1-5</sub> alkyl,
- (3) -CF<sub>3</sub>,
- 5 (4) -halo,
- (5) -NO<sub>2</sub>,
- (6) -N(R<sup>4</sup>)(R<sup>5</sup>),
- (7) -R<sup>6</sup>,
- (8) -C<sub>2-5</sub> alkenyl-R<sup>3</sup>,
- 10 (9) -C<sub>2-5</sub> alkynyl-R<sup>3</sup>,
- (10) -O-R<sup>6</sup>,
- (11) -O-C<sub>1-6</sub> alkyl, and
- (12) -C(O)CH<sub>2</sub>C(O)C(O)OR<sup>7</sup>;

15  $R^2$  is selected from:

- (1) -H,
- (2) -R<sup>3</sup>,
- (3) -C<sub>1-6</sub> alkyl,
- (4) -C<sub>1-6</sub> alkyl substituted with R<sup>3</sup>,
- 20 (5) -O-R<sup>6</sup>,
- (6) -O-C<sub>1-6</sub> alkyl-OR<sup>6</sup>,
- (7) -S(O)<sub>n</sub>-R<sup>6</sup>,
- (8) -C<sub>1-6</sub> alkyl (OR<sup>6</sup>)(R<sup>4</sup>),
- (9) -C<sub>1-6</sub> alkyl (OR<sup>4</sup>)(R<sup>6</sup>),
- 25 (10) -C<sub>0-6</sub> alkyl-N(R<sup>4</sup>)(R<sup>6</sup>),
- (11) -C<sub>1-6</sub> alkyl S(O)<sub>n</sub>-R<sup>6</sup>,
- (12) -C<sub>0-6</sub> alkyl C(O)-R<sup>6</sup>,
- (13) -C<sub>0-6</sub> alkyl C(S)-R<sup>6</sup>,
- (14) -C<sub>0-6</sub> alkyl NR<sup>4</sup>C(O)-R<sup>6</sup>, and
- 30 (15) -C<sub>0-6</sub> alkyl-C(O)N(R<sup>4</sup>)(R<sup>5</sup>);

each R<sup>3</sup> is independently selected from:

- 5 (1) a 5 or 6 membered aromatic or heteroaromatic ring,  
containing 0, 1, 2, 3, or 4 heteroatoms selected from oxygen,  
nitrogen and sulfur, unsubstituted or substituted on a  
nitrogen or carbon atom by 1 to 5 substituents selected from:
- 10 (a) halogen,  
(b) C<sub>1-6</sub> alkyl,  
(c) C<sub>1-6</sub> alkyloxy-,  
(d) phenyl,  
(e) -CF<sub>3</sub>,  
(f) -OCF<sub>3</sub>,  
(g) -CN,  
(h) hydroxy,  
(i) phenyloxy, and  
15 (j) substituted phenyloxy with 1, 2, or 3 substituents  
selected from:  
(i) halogen,  
(ii) C<sub>1-6</sub> alkyl,  
(iii) -CF<sub>3</sub>, and  
20 (iv) hydroxy;
- 25 (2) a 3 to 6 membered saturated ring containing 0 or 1  
heteroatoms selected from oxygen, nitrogen or sulfur,  
unsubstituted or substituted with 0 to 5 substituents selected  
from:
- 30 (a) halogen,  
(b) C<sub>1-6</sub> alkyl,  
(c) C<sub>1-6</sub> alkyloxy-,  
(d) -CF<sub>3</sub>,  
(e) -OCF<sub>3</sub>,  
(f) -CN,  
(g) =O,  
(h) hydroxy;

- (3) unsubstituted or substituted hexahydrothieno[3,4-d]imidazolyl with one or two substituents selected from:
- (a) oxo,
  - (b) halogen,
  - (c) C<sub>1-6</sub> alkyl,
  - (d) C<sub>1-6</sub> alkyloxy-,
  - (e) -CF<sub>3</sub>,
  - (f) -OCF<sub>3</sub>,
  - (g) -CN, and
  - (h) hydroxy;
- (4) a 5 or 6 membered aromatic or heteroaromatic ring, containing 0, 1, or 2 heteroatoms selected from oxygen, nitrogen and sulfur, fused with a phenyl ring; wherein the ring system is unsubstituted or substituted on a nitrogen or carbon atom by 1 to 3 substituents selected from:
- (a) -halogen,
  - (b) -C<sub>1-6</sub> alkyl,
  - (c) -C<sub>1-6</sub> alkyloxy-,
  - (d) -CF<sub>3</sub>,
  - (e) -OCF<sub>3</sub>,
  - (f) -CN, and
  - (g) -hydroxy;
- (5) a 3 to 6 membered saturated ring containing 0 or 1 heteroatoms selected from oxygen, nitrogen or sulfur, fused with a phenyl ring, unsubstituted or substituted with 1 or 2 substituents selected from:
- (a) halogen,
  - (b) C<sub>1-6</sub> alkyl,
  - (c) C<sub>1-6</sub> alkyloxy-,
  - (d) -CF<sub>3</sub>,



- (e)  $-\text{OCF}_3$ ,
- (f)  $-\text{CN}$ ,
- (g)  $=\text{O}$ ,
- (h) hydroxy;

5

- (6) a 5 to 6 membered ring containing 0, 1 or 2 heteroatoms selected from oxygen, nitrogen or sulfur, containing 2 or 3 double bonds, unsubstituted or substituted with 1 or 2 substituents selected from:

10

- (a) halogen,
- (b)  $\text{C}_{1-6}$  alkyl,
- (c)  $\text{C}_{1-6}$  alkyloxy-,
- (d)  $-\text{CF}_3$ ,
- (e)  $-\text{OCF}_3$ ,
- (f)  $-\text{CN}$ ,
- (g)  $=\text{O}$ ,
- (h) hydroxy;

15

each  $\text{R}^4$  is independently selected from:

20

- (1)  $-\text{H}$ ,
- (2)  $-\text{C}_{1-3}$  alkyl,
- (3)  $-\text{CF}_3$ ,
- (4)  $-\text{R}^3$ ,
- (5)  $-\text{C}_{2-3}$  alkenyl,
- (6)  $-\text{C}_{1-3}$  alkyl- $\text{R}^3$ ,
- (7)  $-\text{C}_{2-3}$  alkenyl- $\text{R}^3$ ,
- (8)  $-\text{S}(\text{O})_n-\text{R}^3$ , and
- (9)  $-\text{C}(\text{O})-\text{R}^3$ ;

25

30 each  $\text{R}^5$  is independently selected from:

- (1)  $-\text{H}$ ,
- (2)  $-\text{C}_{1-3}$  alkyl,

- (3)  $-\text{CF}_3$ ,
- (4)  $-\text{R}^3$ ,
- (5)  $-\text{C}_{2-3}$  alkenyl,
- (6)  $-\text{C}_{1-3}$  alkyl- $\text{R}^3$ ,
- 5 (7)  $-\text{C}_{2-3}$  alkenyl- $\text{R}^3$ ,
- (8)  $-\text{S}(\text{O})_n-\text{R}^3$ , and
- (9)  $-\text{C}(\text{O})-\text{R}^3$ ;

each  $R^6$  is independently selected from:

- 10           (1)  $\text{-C}_{1-3}$  alkyl- $\text{R}^3$ , and  
              (2)  $\text{-R}^3$ ;

R7 is selected from:

- 15           (1)    -H, and  
              (2)    C<sub>1-6</sub> alkyl;

**R<sup>8</sup> is selected from:**


- 20           (1)    -H, and  
              (2)    C<sub>1-6</sub> alkyl-oxy-;  
              (3)    C<sub>1-6</sub> alkyl-;

each  $n$  is independently selected from 0, 1 and 2, and


each  $m$  is independently selected from 0, 1, and 2.

Particular compounds of structural formula I include:


- 25 (1)




- (2)



(3)




(4)




5

(5)




(6)




10


(7)




(8)



(9)




(10)




5


(11)



(12)




(13)




10


(14)



(15)




(16)




5


(17)



(18)




(19)




10


(20)



(21)




(22)




5

(23)




(24)




10


(25)




(26)



(27)




(28)




5


(29)



(30)




(31)




10


(32)




(33)



(34)




(35)




5

(36)




(37)




10

(38)






(39)




(40)




5


(41)



(42)




(43)




10


(44)



(45)




(46)




5

(47)




(48)




10


(49)



(50)




(51)




5

(52)




(53)




10

(54)




(55)

, and




and tautomers and pharmaceutically acceptable salts thereof.

In one embodiment of the present invention, structural formula (I) is:




5


In another embodiment of the present invention, structural formula (I) is:



In still another embodiment of the present invention,  
10 structural formula (I) is:




In yet another embodiment of the present invention,  
structural formula (I) is;




15 In one class of compounds of the present invention, A is  
selected from:

- (1) thienyl,  
(2) thiazolyl,  
(3)




5

(4)




(5)



In another class of compounds of the present invention, A is


10 selected from:

- (1) thienyl,  
(2) thiazolyl,  
(3)



15

(4)



In one class of compounds of the present invention, R<sup>1</sup> is  
selected from:

- (1) -H,  
20 (2) -CH<sub>3</sub>,  
(3) -CF<sub>3</sub>,  
(4) -halo,  
(5) -NO<sub>2</sub>,

- (6)  $-N(R^4)(R^5)$ ,  
(7) -phenyl,  
(8) substituted phenyl substituted with 1 or 2 substituents independently selected from:
- 5 (a) halogen,  
(b)  $C_{1-6}$  alkyl,  
(c)  $C_{1-6}$  alkyloxy-,  
(d) phenyl,  
(e)  $-CF_3$ ,  
10 (f)  $-OCF_3$ ,  
(g)  $-CN$ ,  
(h) hydroxy,  
(i) phenyloxy, and  
(j) substituted phenyloxy with 1, 2, or 3 substituents  
15 selected from:  
(i) halogen,  
(ii)  $C_{1-6}$  alkyl,  
(iii)  $-CF_3$ , and  
(iv) hydroxy;
- 20 (9) phenyl  $C_{1-3}$  alkyl-,  
(10) substituted phenyl  $C_{1-3}$  alkyl- substituted with 1 or 2  
substituents independently selected from:
- 25 (a) halogen,  
(b)  $C_{1-6}$  alkyl,  
(c)  $C_{1-6}$  alkyloxy-,  
(d) phenyl,  
(e)  $-CF_3$ ,  
(f)  $-OCF_3$ ,  
(g)  $-CN$ ,  
30 (h) hydroxy,  
(i) phenyloxy, and

(j) substituted phenyloxy with 1, 2, or 3 substituents selected from:

- (i) halogen,
- (ii) C<sub>1-6</sub> alkyl,
- (iii) -CF<sub>3</sub>, and
- (iv) hydroxy;

- (11) -C<sub>2-5</sub> alkenyl-R<sup>3</sup>,
- (12) -C<sub>2-5</sub> alkynyl-R<sup>3</sup>, and
- (13) -C(O)CH<sub>2</sub>C(O)C(O)OR<sup>7</sup>.

10 In another class of compounds of the present invention, R<sup>1</sup> is selected from:

- (1) -H,
- (2) -CH<sub>3</sub>,
- (3) -CF<sub>3</sub>,
- (4) -halo,
- (5) -NO<sub>2</sub>,
- (6) -N(R<sup>4</sup>)(R<sup>5</sup>),
- (7) -phenyl,
- (8) substituted phenyl substituted with 1 or 2 substituents independently selected from:

- (a) halo,
- (b) methyl, and
- (c) methoxy,

(9) phenyl C<sub>1-3</sub> alkyl-,

(10) substituted phenyl C<sub>1-3</sub> alkyl- substituted with 1 or 2 substituents independently selected from:

- (a) halo,
- (b) methyl, and
- (c) methoxy, and

(11) -C<sub>2-5</sub> alkenyl-R<sup>3</sup>.

In still another class of compounds of the present invention, R<sup>1</sup> is hydrogen.

In one class of compounds of the present invention,  $R^2$  is selected from:

- (1)  $-H$ ,
- (2)  $-R^3$ ,
- 5 (3)  $-C_{1-6}$  alkyl,
- (4)  $-C_{1-6}$  alkyl substituted with  $R^3$ ,
- (5)  $-O-R^6$ ,
- (6)  $-O-C_{1-6}$  alkyl- $OR^6$ ,
- (7)  $-S(O)_n-R^6$ ,
- 10 (8)  $-C_{1-6}$  alkyl  $(OR^6)(R^4)$ ,
- (9)  $-C_{1-6}$  alkyl  $(OR^4)(R^6)$ ,
- (10)  $-C_{0-6}$  alkyl- $N(R^4)(R^6)$ ,
- (11)  $-C_{1-6}$  alkyl  $S(O)_n-R^6$ ,
- (12)  $-C_{0-6}$  alkyl  $C(O)-R^6$ ,
- 15 (13)  $-C_{0-6}$  alkyl  $C(S)-R^6$ ,
- (14)  $-C_{0-6}$  alkyl  $NR^4C(O)-R^6$ , and
- (15)  $-C_{0-6}$  alkyl- $C(O)N(R^4)(R^5)$ .

In another class of compounds of the present invention,  $R^2$  is selected from:

- 20 (1)  $-H$ ,
- (2)  $-R^3$ ,
- (3)  $-C_{1-6}$  alkyl,
- (4)  $-C_{1-6}$  alkyl substituted with  $R^3$ ,
- (5)  $-O-R^6$ ,
- 25 (6)  $-S(O)_n-R^6$ ,
- (7)  $-C_{1-6}$  alkyl  $(OR^6)(R^4)$ ,
- (8)  $-C_{1-6}$  alkyl  $(OR^4)(R^6)$ ,
- (9)  $-C_{0-6}$  alkyl- $N(R^4)(R^6)$ ,
- (10)  $-C_{1-6}$  alkyl  $S(O)_n-R^6$ ,
- 30 (11)  $-C_{0-6}$  alkyl  $C(O)-R^6$ ,
- (12)  $-C_{0-6}$  alkyl  $NR^4C(O)-R^6$ , and



(13)  $-C_{0-6}$  alkyl- $C(O)N(R^4)(R^5)$ .

In one class of compounds of the present invention,  $R^3$  is selected from:

- (1) phenyl;
- 5 (2) substituted phenyl with 1, 2, or 3 substituents independently selected from:
  - (a) halogen,
  - (b)  $C_{1-6}$  alkyl,
  - (c)  $C_{1-6}$  alkyloxy-,
  - 10 (d) phenyl,
  - (e)  $-CF_3$ ,
  - (f)  $-OCF_3$ ,
  - (g)  $-CN$ ,
  - (h) hydroxy,
  - 15 (i) phenyloxy, and
  - (j) substituted phenyloxy with 1, 2, or 3 substituents selected from:
    - (i) halogen,
    - (ii)  $C_{1-6}$  alkyl,
    - 20 (iii)  $-CF_3$ , and
    - (iv) hydroxy;
- (3) thienyl;
- (4) substituted thienyl substituted on a carbon atom with one or two substituents independently selected from:
  - 25 (a) halogen,
  - (b)  $C_{1-6}$  alkyl,
  - (c)  $C_{1-6}$  alkyloxy-,
  - (d) phenyl,
  - (e)  $-CF_3$ ,
  - 30 (f)  $-OCF_3$ ,
  - (g)  $-CN$ ,
  - (h) hydroxy,

- (i) phenyloxy, and  
(j) substituted phenyloxy with 1, 2, or 3 substituents  
selected from:  
(i) halogen,  
5 (ii) C<sub>1-6</sub> alkyl,  
(iii) -CF<sub>3</sub>, and  
(iv) hydroxy;  
(5) pyridyl;  
(6) substituted pyridyl substituted on a carbon atom with one or  
10 two substituents independently selected from:  
(a) halogen,  
(b) C<sub>1-6</sub> alkyl,  
(c) C<sub>1-6</sub> alkyloxy-,  
(d) phenyl,  
15 (e) -CF<sub>3</sub>,  
(f) -OCF<sub>3</sub>,  
(g) -CN,  
(h) hydroxy,  
(i) phenyloxy, and  
20 (j) substituted phenyloxy with 1, 2, or 3 substituents  
selected from:  
(i) halogen,  
(ii) C<sub>1-6</sub> alkyl,  
(iii) -CF<sub>3</sub>, and  
25 (iv) hydroxy;  
(7) imidazolyl;  
(8) substituted imidazolyl substituted on a carbon atom with  
one or two substituents independently selected from:  
(a) halogen,  
30 (b) C<sub>1-6</sub> alkyl,  
(c) C<sub>1-6</sub> alkyloxy-,  
(d) phenyl,  
(e) -CF<sub>3</sub>,

- 5 (f)  $-\text{OCF}_3$ ,  
(g)  $-\text{CN}$ ,  
(h) hydroxy,  
(i) phenyloxy, and  
(j) substituted phenyloxy with 1, 2, or 3 substituents  
selected from:  
(i) halogen,  
(ii)  $\text{C}_{1-6}$  alkyl,  
(iii)  $-\text{CF}_3$ , and  
10 (iv) hydroxy;  
(9) pyrrolyl;  
(10) substituted pyrrolyl substituted on a carbon atom with one  
or two substituents independently selected from:  
(a) halogen,  
15 (b)  $\text{C}_{1-6}$  alkyl,  
(c)  $\text{C}_{1-6}$  alkyloxy-,  
(d) phenyl,  
(e)  $-\text{CF}_3$ ,  
(f)  $-\text{OCF}_3$ ,  
20 (g)  $-\text{CN}$ ,  
(h) hydroxy,  
(i) phenyloxy, and  
(j) substituted phenyloxy with 1, 2, or 3 substituents  
selected from:  
25 (i) halogen,  
(ii)  $\text{C}_{1-6}$  alkyl,  
(iii)  $-\text{CF}_3$ , and  
(iv) hydroxy;  
(11) pyrazolyl;  
30 (12) substituted pyrazolyl substituted on a carbon atom with one  
or two substituents independently selected from:  
(a) halogen,  
(b)  $\text{C}_{1-6}$  alkyl,

- (c) C<sub>1-6</sub> alkyloxy-,  
(d) phenyl,  
(e) -CF<sub>3</sub>,  
(f) -OCF<sub>3</sub>,  
5 (g) -CN,  
(h) hydroxy,  
(i) phenyloxy, and  
(j) substituted phenyloxy with 1, 2, or 3 substituents  
selected from:  
10 (i) halogen,  
(ii) C<sub>1-6</sub> alkyl,  
(iii) -CF<sub>3</sub>, and  
(iv) hydroxy;  
(13) C<sub>3-6</sub> cycloalkyl;  
15 (14) substituted C<sub>3-6</sub> cycloalkyl with 1 or 2 substituents  
independently selected from:  
(a) halogen,  
(b) C<sub>1-6</sub> alkyl,  
(c) C<sub>1-6</sub> alkyloxy-,  
20 (d) -CF<sub>3</sub>,  
(e) -OCF<sub>3</sub>,  
(f) -CN,  
(g) =O, and  
(h) hydroxy;  
25 (15) piperidinyl;  
(16) substituted piperidinyl substituted on a carbon atom with  
one or two substituents independently selected from:  
(a) halogen,  
(b) C<sub>1-6</sub> alkyl,  
30 (c) C<sub>1-6</sub> alkyloxy-,  
(d) -CF<sub>3</sub>,  
(e) -OCF<sub>3</sub>,

- (f) -CN,
- (g) =O, and
- (h) hydroxy;
- (17) morpholinyl;
- 5 (18) substituted morpholinyl substituted at a carbon or nitrogen atom with 1 or 2 independently selected from:
  - (a) halogen,
  - (b) C<sub>1-6</sub> alkyl,
  - (c) C<sub>1-6</sub> alkyloxy-,
  - 10 (d) -CF<sub>3</sub>,
  - (e) -OCF<sub>3</sub>,
  - (f) -CN,
  - (g) =O, and
  - (h) hydroxy;
- 15 (19) naphthyl,
- (20) substituted naphthyl with 1, 2, or 3 substituents independently selected from:
  - (a) -halogen,
  - (b) -C<sub>1-6</sub> alkyl,
  - 20 (c) -C<sub>1-6</sub> alkyloxy-,
  - (d) -CF<sub>3</sub>,
  - (e) -OCF<sub>3</sub>,
  - (f) -CN, and
  - (g) -hydroxy;
- 25 (21) indolyl;
- (22) substituted indolyl substituted on a carbon atom with one or two substituents independently selected from:
  - (a) -halogen,
  - (b) -C<sub>1-6</sub> alkyl,
  - 30 (c) -C<sub>1-6</sub> alkyloxy-,
  - (d) -CF<sub>3</sub>,
  - (e) -OCF<sub>3</sub>,
  - (f) -CN, and

- (g) -hydroxy;
- (23) C<sub>3-6</sub> cycloalkyl fused with a phenyl ring
- (24) substituted C<sub>3-6</sub> cycloalkyl fused with a phenyl ring  
substituted on a carbon atom with one or two substituents  
independently selected from:
- (a) halogen,
- (b) C<sub>1-6</sub> alkyl,
- (c) C<sub>1-6</sub> alkyloxy-,
- (d) -CF<sub>3</sub>,
- (e) -OCF<sub>3</sub>,
- (f) -CN,
- (g) =O, and
- (h) hydroxy.
- In another class of compounds of the present invention, R<sup>3</sup>  
is selected from:
- (1) phenyl;
- (2) substituted phenyl with 1, 2, or 3 substituents independently  
selected from:
- (a) halogen,
- (b) C<sub>1-6</sub> alkyl,
- (c) C<sub>1-6</sub> alkyloxy-,
- (d) phenyl,
- (e) -CF<sub>3</sub>,
- (f) -OCF<sub>3</sub>,
- (g) -CN,
- (h) hydroxy,
- (i) phenyloxy, and
- (j) substituted phenyloxy with 1, 2, or 3 substituents  
selected from:
- (i) halogen,
- (ii) C<sub>1-6</sub> alkyl,
- (iii) -CF<sub>3</sub>, and
- (iv) hydroxy;

- (3) thienyl;
- (4) substituted thienyl substituted on a carbon atom with one or two substituents independently selected from:
- 5 (a) halogen,  
(b) C<sub>1-6</sub> alkyl,  
(c) C<sub>1-6</sub> alkyloxy-,  
(d) phenyl,  
(e) -CF<sub>3</sub>,  
(f) -OCF<sub>3</sub>,  
10 (g) -CN,  
(h) hydroxy,  
(i) phenyloxy, and  
(j) substituted phenyloxy with 1, 2, or 3 substituents selected from:
- 15 (i) halogen,  
(ii) C<sub>1-6</sub> alkyl,  
(iii) -CF<sub>3</sub>, and  
(iv) hydroxy;
- (5) pyridyl;
- 20 (6) substituted pyridyl substituted on a carbon atom with one or two substituents independently selected from:
- (a) halogen,  
(b) C<sub>1-6</sub> alkyl,  
(c) C<sub>1-6</sub> alkyloxy-,  
25 (d) phenyl,  
(e) -CF<sub>3</sub>,  
(f) -OCF<sub>3</sub>,  
(g) -CN,  
(h) hydroxy,  
30 (i) phenyloxy, and  
(j) substituted phenyloxy with 1, 2, or 3 substituents selected from:  
(i) halogen,

- (ii) C<sub>1-6</sub> alkyl,
  - (iii) -CF<sub>3</sub>, and
  - (iv) hydroxy;
- 5 (7) imidazolyl;
- (8) pyrrolyl;
- (9) pyrazolyl;
- (10) C<sub>3-6</sub> cycloalkyl,
- (11) substituted C<sub>3-6</sub> cycloalkyl with 1 or 2 substituents independently selected from:
- 10 (a) halogen,
- (b) C<sub>1-6</sub> alkyl,
- (c) C<sub>1-6</sub> alkyloxy-,
- (d) -CF<sub>3</sub>,
- (e) -OCF<sub>3</sub>,
- 15 (f) -CN,
- (g) =O, and
- (h) hydroxy;
- (12) piperidinyl;
- (13) substituted piperidinyl substituted on a carbon atom with one or two substituents independently selected from:
- 20 (a) halogen,
- (b) C<sub>1-6</sub> alkyl,
- (c) C<sub>1-6</sub> alkyloxy-,
- (d) -CF<sub>3</sub>,
- 25 (e) -OCF<sub>3</sub>,
- (f) -CN,
- (g) =O, and
- (h) hydroxy;
- (14) morpholinyl;
- 30 (15) naphthyl;
- (16) indolyl, and
- (17) C<sub>3-6</sub> cycloalkyl fused with a phenyl ring.



In still another class of compounds of the present invention,  
R<sup>3</sup> is selected from:

- (1) phenyl,
- (2) substituted phenyl with 1, 2, or 3 substituents independently  
5 selected from:
  - (a) halogen selected from -F, -Cl, -Br,,
  - (b) CH<sub>3</sub>,
  - (c) methoxy-,
  - (d) phenyl,
  - 10 (e) -CF<sub>3</sub>,
  - (f) -OCF<sub>3</sub>,
  - (g) -CN,
  - (h) hydroxy,
  - (i) phenyloxy, and
  - 15 (j) substituted phenyloxy with 1, 2, or 3 substituents  
selected from:
    - (i) halogen selected from -F, -Cl, -Br,
    - (ii) -CH<sub>3</sub>,
    - (iii) -CF<sub>3</sub>, and
    - 20 (iv) hydroxy;
- (3) thienyl,
- (5) pyridyl,
- (7) imidazolyl,
- (8) pyrrolyl,
- 25 (9) pyrazolyl,
- (10) C<sub>3-6</sub> cycloalkyl,
- (12) piperidinyl,
- (14) morpholinyl,
- (15) naphthyl,
- 30 (16) indolyl, and
- (17) C<sub>3-6</sub> cycloalkyl fused with a phenyl ring.

In one class of compounds of the present invention, R<sup>4</sup> is  
selected from:

- (1) -H,  
(2) -C<sub>1-3</sub> alkyl,  
(3) -CF<sub>3</sub>,  
(4) -R<sup>3</sup>,  
5 (5) -C<sub>2-3</sub> alkenyl,  
(6) -C<sub>1-3</sub> alkyl-R<sup>3</sup>,  
(7) -C<sub>2-3</sub> alkenyl-R<sup>3</sup>,  
(8) -S(O)<sub>n</sub>-R<sup>3</sup>, and  
(9) -C(O)-R<sup>3</sup>.

10 In another class of compounds of the present invention, R<sup>4</sup>  
is selected from:

- (1) -H,  
(2) -C<sub>1-3</sub> alkyl,  
(3) -CF<sub>3</sub>,  
15 (4) -R<sup>3</sup>,  
(5) -C<sub>2-3</sub> alkenyl,  
(6) -C<sub>1-3</sub> alkyl-R<sup>3</sup>, and  
(7) -S(O)<sub>n</sub>-R<sup>3</sup>.

20 In one class of compounds of the present invention, R<sup>5</sup> is  
selected from:

- (1) -H,  
(2) -C<sub>1-3</sub> alkyl,  
(3) -CF<sub>3</sub>,  
(4) -R<sup>3</sup>,  
25 (5) -C<sub>2-3</sub> alkenyl,  
(6) -C<sub>1-3</sub> alkyl-R<sup>3</sup>,  
(7) -C<sub>2-3</sub> alkenyl-R<sup>3</sup>,  
(8) -S(O)<sub>n</sub>-R<sup>3</sup>, and  
(9) -C(O)-R<sup>3</sup>.

30 In another class of compounds of the present invention, R<sup>5</sup>  
is selected from:

- (1) -H,
- (2) -C<sub>1-3</sub> alkyl,
- (3) -CF<sub>3</sub>,
- (4) -R<sup>3</sup>,
- 5 (5) -C<sub>2-3</sub> alkenyl,
- (6) -C<sub>1-3</sub> alkyl-R<sup>3</sup>,
- (7) -C<sub>2-3</sub> alkenyl-R<sup>3</sup>, and
- (8) -S(O)<sub>n</sub>-R<sup>3</sup>.

10 In one class of compounds of the present invention, R<sup>7</sup> is hydrogen.


In one class of compounds of the present invention, R<sup>8</sup> is selected from: hydrogen, methyl and methoxy.

Also included within the present invention are pharmaceutical compositions useful for inhibiting HIV integrase, comprising an effective amount of a compound of this invention, and a pharmaceutically acceptable carrier. Pharmaceutical compositions useful for treating infection by HIV, or for treating AIDS or ARC, are also encompassed by the present invention, as well as a method of inhibiting HIV integrase, and a method of treating infection by HIV, or of treating AIDS or ARC. Additionally, the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present invention in combination with a therapeutically effective amount of an AIDS treatment agent selected from:

- 25 (1) an AIDS antiviral agent,
- (2) an anti-infective agent, and
- (3) an immunomodulator.

The compounds of the present invention may have asymmetric centers and may occur, except when specifically noted, as mixtures of stereoisomers or as individual diastereomers, or enantiomers, with all isomeric forms being included in the present invention.

As is recognized by one of ordinary skill in the art, the diketo-acid/ester compounds of the present invention exist as tautomers, and thus by using the phrase "and tautomers thereof" in describing compounds of structural formula (I), Applicants also intend the following tautomeric forms of the same compound (Ia) and (Ib):



By naming or referring to compound (I) and tautomers thereof, it is understood for the purposes of the present application that the tautomers (Ia) and (Ib) are also intended. Similarly, by referring to compound (Ia), it is understood for the purposes of the present application that the tautomers (I) and (Ib) are also intended. The same holds true for references to tautomer (Ib).

When any variable (e.g., R<sup>3</sup>, R<sup>4</sup>, etc.) occurs more than one time in any constituent or in formula I, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.


The compounds of the present inventions are useful in the inhibition of HIV integrase, the prevention or treatment of infection by human immunodeficiency virus (HIV) and the treatment of consequent pathological conditions such as AIDS. Treating AIDS or preventing or treating infection by HIV is defined as including, but not limited to, treating a wide range of states of HIV infection: AIDS, ARC (AIDS

related complex), both symptomatic and asymptomatic, and actual or potential exposure to HIV. For example, the compounds of this invention are useful in treating infection by HIV after suspected past exposure to HIV by e.g., blood transfusion, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.

The compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds. For example, the compounds of this invention are useful for isolating enzyme mutants, which are excellent screening tools for more powerful antiviral compounds. Furthermore, the compounds of this invention are useful in establishing or determining the binding site of other antivirals to HIV integrase, e.g., by competitive inhibition. Thus the compounds of this invention are commercial products to be sold for these purposes.

The present invention also provides for the use of a compound of structural formula (I) to make a pharmaceutical composition useful for inhibiting HIV integrase and in the treatment of AIDS or ARC.


Compounds of structural formula (I) wherein A is thienyl may be made according to the procedures in Schemes AI, AII, BI, CI, CII, DI, EI, FI, FII, and FIII. Compounds of structural formula (I) wherein A is thiazolyl may be prepared according to the procedures in Scheme GI.



AI (3)


i. NaOH, MeOH-H<sub>2</sub>O-THF

ii. HCl




AI(4)

## Scheme AII




AII(1)



X = CH, N  
R = H, F, F<sub>2</sub>





NaH, DMSO



AII(2a-e)




AII (3a-e)




AII (4a-e)

## Scheme BI









BI(3a-d)


$n\text{-BuLi}$ ,  $\text{Et}_2\text{O}$ ,  $\text{CH}_3\text{CONCH}_3(\text{OCH}_3)$



BI(4a-d)




LDA, THF



BI(5a-d)


i. NaOH, MeOH-H<sub>2</sub>O-THF

ii. HCl




BI(6a-d)


Scheme BII




BII(1)




acetone



BII(2)




NaOEt, THF



BII(3)


i. NaOH, MeOH-H<sub>2</sub>O-THF


ii. HCl



BII(4)


## Scheme CI






CI(3a-d)

$n\text{-BuLi}$ ,  $\text{Et}_2\text{O}$ ,  $\text{CH}_3\text{CONCH}_3(\text{OCH}_3)$




CI(4a-d)


## Scheme CI (continue)



CI (4a-d)




LDA, THF



CI (5a-d)


i. NaOH, MeOH-H<sub>2</sub>O-THF


ii. HCl



CI (6a-d)


## Scheme CII






i. NaOH, MeOH-H<sub>2</sub>O-THF


ii. HCl




Scheme DI




n-BuLi, Et<sub>2</sub>O,









$\text{BF}_3 \cdot \text{Et}_2\text{O}$ ,  $\text{Et}_3\text{SiH}$ ,  $\text{CH}_2\text{Cl}_2$





$n\text{-BuLi}$ ,  $\text{Et}_2\text{O}$ ,  $\text{CH}_3\text{CONCH}_3(\text{OCH}_3)$





## Scheme DI (continue)



DI (4a-c)




DI (5a-c)





DI (6a-c)

## Scheme EI



BI(1)




BI(2d)




Reaction arrow with reagents:  $\text{NaH}$ ,  $\text{DMSO}$ ,  $\text{RX}$ .

R = Bn, Ph, Me




EI (1a-c)

n-BuLi, Et<sub>2</sub>O, CH<sub>3</sub>CONC





EI (2a-c)



## Scheme EI (continue)



EI (3a-c)




EI (4a-c)





EI (5a-c)

## Scheme FI




$R' = H, R$

$R = \text{Bn}, n\text{-Pr}, \text{allyl}, \text{Me}$




NaOEt, THF




i. NaOH, MeOH-H<sub>2</sub>O-THF


ii. HCl




## Scheme FII










Scheme FIII




RSO<sub>2</sub>Cl, pyridine



NaHMDS, DMSO, R'X




NaOEt, THF









i. NaOH, MeOH-H<sub>2</sub>O-THF

ii. HCl








## Scheme GI






Scheme GII






NaOEt, THF



i. NaOH, MeOH-H<sub>2</sub>O-THF

ii. HCl



The compounds of the present invention may be administered in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" is intended to include all

5 acceptable salts such as acetate, lactobionate, benzenesulfonate, laurate, benzoate, malate, bicarbonate, maleate, bisulfate, mandelate, bitartrate, mesylate, borate, methylbromide, bromide, methylnitrate, calcium edetate, methylsulfate, camsylate, mucate, carbonate, napsylate, chloride, nitrate, clavulanate, N-methylglucamine, citrate, ammonium

10 salt, dihydrochloride, oleate, edetate, oxalate, edisylate, pamoate (embonate), estolate, palmitate, esylate, pantothenate, fumarate, phosphate/diphosphate, gluceptate, polygalacturonate, gluconate, salicylate, glutamate, stearate, glycolylarsanilate, sulfate, hexylresorcinatate, subacetate, hydrabamine, succinate, hydrobromide,

15 tannate, hydrochloride, tartrate, hydroxynaphthoate, teclate, iodide, tosylate, isothionate, triethiodide, lactate, pantoate, valerate, and the like which can be used as a dosage form for modifying the solubility or hydrolysis characteristics or can be used in sustained release or pro-drug formulations. Depending on the particular functionality of the

20 compound of the present invention, pharmaceutically acceptable salts of the compounds of this invention include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such as ammonia, ethylenediamine, N-methylglutamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chlorprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, and tetramethylammonium hydroxide. These salts may be prepared by standard procedures, e.g. by reacting a free acid with a suitable organic or inorganic base. Where a basic group is present, such as amino, an

30 acidic salt, i.e. hydrochloride, hydrobromide, acetate, pamoate, and the like, can be used as the dosage form.

Also, in the case of an acid (-COOH) or alcohol group being present, pharmaceutically acceptable esters can be employed, e.g. acetate, maleate, pivaloyloxymethyl, and the like, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.

For these purposes, the compounds of the present invention may be administered orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques), by inhalation spray, or rectally, in dosage unit formulations containing conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles.

The terms "administration of" and or "administering a" compound should be understood to mean providing a compound of the invention or a prodrug of a compound of the invention to the individual in need of treatment.

Thus, in accordance with the present invention there is further provided a method of treating and a pharmaceutical composition for treating HIV infection and AIDS. The treatment involves administering to a patient in need of such treatment a pharmaceutical composition comprising a pharmaceutical carrier and a therapeutically-effective amount of a compound of the present invention.

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

These pharmaceutical compositions may be in the form of orally-administrable suspensions or tablets, nasal sprays, sterile injectible preparations, for example, as sterile injectible aqueous or oleagenous suspensions or suppositories.

When administered orally as a suspension, these compositions are prepared according to techniques well-known in the

art of pharmaceutical formulation and may contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners/flavoring agents known in the art. As immediate release  
5 tablets, these compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art.

When administered by nasal aerosol or inhalation, these  
10 compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.

15 The injectible solutions or suspensions may be formulated according to known art, using suitable non-toxic, parenterally-acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland,  
20 fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.

When rectally administered in the form of suppositories, these compositions may be prepared by mixing the drug with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters  
25 of polyethylene glycols, which are solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.

The compounds of this invention can be administered orally to humans in a dosage range of 1 to 1000 mg/kg body weight in divided doses. One preferred dosage range is 0.1 to 200 mg/kg body weight orally  
30 in divided doses. Another preferred dosage range is 0.5 to 100 mg/kg body weight orally in divided doses. For oral administration, the compositions are preferably provided in the form of tablets containing 1.0 to 1000 milligrams of the active ingredient, particularly 1.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0,  
35 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of the active ingredient



for the symptomatic adjustment of the dosage to the patient to be treated. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound  
5 employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

The present invention is also directed to combinations of the  
10 HIV integrase inhibitor compounds with one or more agents useful in the treatment of AIDS. For example, the compounds of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of the AIDS antivirals, immunomodulators, antiinfectives, or vaccines, such as those  
15 in the following table.

ANTIVIRALS

<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
097	Hoechst/Bayer	HIV infection, AIDS, ARC (non-nucleoside reverse transcriptase (RT) inhibitor)
Amprenavir 141 W94 GW141	Glaxo Wellcome	HIV infection, AIDS, ARC (protease inhibitor)
Abacavir (1592U89)	Glaxo Wellcome	HIV infection, AIDS, ARC (RT inhibitor)
Acemannan	Carrington Labs (Irving, TX)	ARC
Acyclovir	Burroughs Wellcome	HIV infection, AIDS, ARC, in combination with AZT
AD-439	Tanox Biosystems	HIV infection, AIDS, ARC
AD-519	Tanox Biosystems	HIV infection, AIDS, ARC
Adefovir dipivoxil AL-721	Gilead Sciences Ethigen (Los Angeles, CA)	HIV infection ARC, PGL HIV positive, AIDS
Alpha Interferon	Glaxo Wellcome	Kaposi's sarcoma, HIV in combination w/Retrovir

Ansamycin LM 427	Adria Laboratories (Dublin, OH) Erbamont (Stamford, CT)	ARC
Antibody which neutralizes pH labile alpha aberrant Interferon AR177	Advanced Biotherapy Concepts (Rockville, MD)	AIDS, ARC
beta-fluoro-ddA	Aronex Pharm	HIV infection, AIDS, ARC
BMS-232623 (CGP-73547)	Nat'l Cancer Institute	AIDS-associated diseases
BMS-234475 (CGP-61755)	Bristol-Myers Squibb/ Novartis	HIV infection, AIDS, ARC (protease inhibitor)
CI-1012 Cidofovir	Bristol-Myers Squibb/ Novartis	HIV infection, AIDS, ARC (protease inhibitor)
CI-1012 Cidofovir	Warner-Lambert Gilead Science	HIV-1 infection CMV retinitis, herpes, papillomavirus
Curdlan sulfate Cytomegalovirus immune globin	AJI Pharma USA MedImmune	HIV infection CMV retinitis
Cytovene Ganciclovir	Syntex	sight threatening CMV peripheral CMV retinitis
Delaviridine	Pharmacia-Upjohn	HIV infection, AIDS, ARC (RT inhibitor)
Dextran Sulfate	Ueno Fine Chem. Ind. Ltd. (Osaka, Japan)	AIDS, ARC, HIV positive asymptomatic

ddC Dideoxycytidine	Hoffman-La Roche	HIV infection, AIDS, ARC
ddI Dideoxyinosine	Bristol-Myers Squibb	HIV infection, AIDS, ARC; combination with AZT/d4T
DMP-450	AVID (Camden, NJ)	HIV infection, AIDS, ARC (protease inhibitor)
Efavirenz (DMP 266) ((-) 6-Chloro-4(S)- cyclopropylethynyl-4(S)- trifluoro-methyl-1,4- dihydro-2H-3,1- benzoxazin-2-one) STOCRIN, EL10	DuPont Merck	HIV infection, AIDS, ARC (non-nucleoside RT inhibitor)
Famciclovir	Elan Corp, PLC (Gainesville, GA) Smith Kline	HIV infection  herpes zoster, herpes simplex
FTC	Emory University	HIV infection, AIDS, ARC (reverse transcriptase inhibitor)
GS 840	Gilead	HIV infection, AIDS, ARC (reverse transcriptase inhibitor)
HBY097	Hoechst Marion Roussel	HIV infection, AIDS, ARC (non-nucleoside reverse transcriptase inhibitor)

Hypericin	VIMRx Pharm.	HIV infection, AIDS, ARC
Recombinant Human Interferon Beta	Triton Biosciences (Alameda, CA)	AIDS, Kaposi's sarcoma, ARC
Interferon alfa-n3	Interferon Sciences	ARC, AIDS
Indinavir	Merck	HIV infection, AIDS, ARC, asymptomatic HIV positive, also in combination with AZT/ddI/ddC
ISIS 2922	ISIS Pharmaceuticals	CMV retinitis
KNI-272	Nat'l Cancer Institute	HIV-assoc. diseases
Lamivudine, 3TC	Glaxo Wellcome	HIV infection, AIDS, ARC (reverse transcriptase inhibitor); also with AZT
Lobucavir	Bristol-Myers Squibb	CMV infection
Nelfinavir	Agouron Pharmaceuticals	HIV infection, AIDS, ARC (protease inhibitor)
Nevirapine	Boeheringer Ingleheim	HIV infection, AIDS, ARC (RT inhibitor)
Novapren	Novaferon Labs, Inc. (Akron, OH)	HIV inhibitor
Peptide T Octapeptide Sequence	Peninsula Labs (Belmont, CA)	AIDS
Trisodium Phosphonoformate	Astra Pharm. Products, Inc	CMV retinitis, HIV infection, other CMV infections

PNU-140690	Pharmacia Upjohn	HIV infection, AIDS, ARC (protease inhibitor)
Probucol	Vyrex	HIV infection, AIDS
RBC-CD4	Sheffield Med. Tech (Houston TX)	HIV infection, AIDS, ARC
Ritonavir	Abbott	HIV infection, AIDS, ARC (protease inhibitor)
Saquinavir	Hoffmann-LaRoche	HIV infection, AIDS, ARC (protease inhibitor)
Stavudine; d4T Didehydrodeoxy- thymidine	Bristol-Myers Squibb	HIV infection, AIDS, ARC
Valaciclovir	Glaxo Wellcome	genital HSV & CMV infections
Virazole	Viratek/ICN	asymptomatic HIV
Ribavirin	(Costa Mesa, CA)	positive, LAS, ARC
VX-478	Vertex	HIV infection, AIDS, ARC
Zalcitabine	Hoffmann-La Roche	HIV infection, AIDS, ARC, with AZT
Zidovudine; AZT	Glaxo Wellcome	HIV infection, AIDS, ARC, Kaposi's sarcoma, in combination with other therapies

IMMUNO-MODULATORS

<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
AS-101	Wyeth-Ayerst	AIDS

Bropirimine	Pharmacia Upjohn	advanced AIDS
Acemannan	Carrington Labs, Inc. (Irving, TX)	AIDS, ARC
CL246,738	American Cyanamid Lederle Labs	AIDS, Kaposi's sarcoma
EL10	Elan Corp, PLC (Gainesville, GA)	HIV infection
FP-21399	Fuki ImmunoPharm	blocks HIV fusion with CD4+ cells
Gamma Interferon	Genentech	ARC, in combination w/TNF (tumor necrosis factor)
Granulocyte Macrophage Colony Stimulating Factor	Genetics Institute Sandoz	AIDS
Granulocyte Macrophage Colony Stimulating Factor	Hoeschst-Roussel Immunex	AIDS
Granulocyte Macrophage Colony Stimulating Factor	Schering-Plough	AIDS, combination w/AZT
HIV Core Particle Immunostimulant	Rorer	seropositive HIV
IL-2	Cetus	AIDS, in combination w/AZT
Interleukin-2	Hoffman-La Roche	AIDS, ARC, HIV, in combination w/AZT
IL-2	Immunex	AIDS, increase in CD4 cell counts
IL-2	Chiron	
Interleukin-2 (aldeslukin)		

Immune Globulin Intravenous (human)	Cutter Biological (Berkeley, CA)	pediatric AIDS, in combination w/AZT
IMREG-1	Imreg (New Orleans, LA)	AIDS, Kaposi's sarcoma, ARC, PGL
IMREG-2	Imreg (New Orleans, LA)	AIDS, Kaposi's sarcoma, ARC, PGL
Imuthiol Diethyl Dithio Carbamate	Merieux Institute	AIDS, ARC
Alpha-2 Interferon	Schering Plough	Kaposi's sarcoma w/AZT, AIDS
Methionine- Enkephalin	TNI Pharmaceutical (Chicago, IL)	AIDS, ARC
MTP-PE	Ciba-Geigy Corp.	Kaposi's sarcoma
Muramyl-Tripeptide Granulocyte Colony Stimulating Factor	Amgen	AIDS, in combination w/AZT
Remune	Immune Response Corp.	immunotherapeutic
rCD4 Recombinant Soluble Human CD4	Genentech	AIDS, ARC
rCD4-IgG hybrids		AIDS, ARC
Recombinant Soluble Human CD4	Biogen	AIDS, ARC
Interferon Alfa 2a	Hoffman-La Roche	Kaposi's sarcoma AIDS, ARC, in combination w/AZT
SK&F106528 Soluble T4	Smith Kline	HIV infection



Thymopentin	Immunobiology Research Institute (Annandale, NJ)	HIV infection
Tumor Necrosis Factor; TNF	Genentech	ARC, in combination w/gamma Interferon

### ANTI-INFECTIVES

<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
Clindamycin with Primaquine	Pharmacia Upjohn	PCP
Fluconazole	Pfizer	cryptococcal meningitis, candidiasis
Pastille	Squibb Corp.	prevention of
Nystatin Pastille		oral candidiasis
Ornidyl	Merrell Dow	PCP
Eflornithine		
Pentamidine	LyphoMed	PCP treatment
Isethionate (IM & IV)	(Rosemont, IL)	
Trimethoprim		antibacterial
Trimethoprim/sulfa		antibacterial
Piritrexim	Burroughs Wellcome	PCP treatment
Pentamidine	Fisons Corporation	PCP prophylaxis
isethionate for inhalation		
Spiramycin	Rhone-Poulenc	cryptosporidial diarrhea
Intraconazole-	Janssen Pharm.	histoplasmosis;
R51211		cryptococcal meningitis
Trimetrexate	Warner-Lambert	PCP

OTHER

<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
Daunorubicin	NeXstar, Sequus	Karposi's sarcoma
Recombinant Human Erythropoietin	Ortho Pharm. Corp.	severe anemia assoc. with AZT therapy
Recombinant Human Growth Hormone	Serono	AIDS-related wasting, cachexia
Megestrol Acetate	Bristol-Myers Squibb	treatment of anorexia assoc. w/AIDS
Testosterone	Alza, Smith Kline	AIDS-related wasting
Total Enteral Nutrition	Norwich Eaton Pharmaceuticals	diarrhea and malabsorption related to AIDS

5 It will be understood that the scope of combinations of the compounds of this invention with AIDS antivirals, immunomodulators, anti-infectives or vaccines is not limited to the list in the above Table, but includes in principle any combination with any pharmaceutical composition useful for the treatment of AIDS.

10 Preferred combinations are simultaneous or alternating treatments of with a compound of the present invention and an inhibitor of HIV protease and/or a non-nucleoside inhibitor of HIV reverse transcriptase. An optional fourth component in the combination is a nucleoside inhibitor of HIV reverse transcriptase, such as AZT, 3TC, ddC or ddI. A preferred inhibitor of HIV protease is indinavir, which is  
15 the sulfate salt of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(4-(3-pyridyl-methyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide ethanolate, and is synthesized according to U.S. 5,413,999. Indinavir is generally administered at a dosage of 800 mg three times a day. Other preferred protease inhibitors are nelfinavir  
20 and ritonavir. Another preferred inhibitor of HIV protease is saquinavir which is administered in a dosage of 600 or 1200 mg tid. Preferred non-

nucleoside inhibitors of HIV reverse transcriptase include efavirenz. The preparation of ddC, ddI and AZT are also described in EPO 0,484,071. These combinations may have unexpected effects on limiting the spread and degree of infection of HIV. Preferred combinations  
5 include those with the following (1) indinavir with efavirenz, and, optionally, AZT and/or 3TC and/or ddI and/or ddC; (2) indinavir, and any of AZT and/or ddI and/or ddC and/or 3TC, in particular, indinavir and AZT and 3TC; (3) stavudine and 3TC and/or zidovudine; (4) zidovudine and lamivudine and 141W94 and 1592U89; (5) zidovudine and  
10 lamivudine.

In such combinations the compound of the present invention and other active agents may be administered separately or in conjunction. In addition, the administration of one element may be prior to, concurrent to, or subsequent to the administration of other  
15 agent(s).

It will be understood that the scope of combinations of the compounds of this invention with AIDS antivirals, immunomodulators, anti-infectives or vaccines is not limited to the list in the above Table, but includes in principle any combination with any pharmaceutical  
20 composition useful for the treatment of AIDS.

Indinavir is an inhibitor of HIV protease and is the sulfate salt of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(4-(3-pyridyl-methyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide ethanolate, and is synthesized according to U.S. 5,413,999.  
25 Indinavir is generally administered at a dosage of 800 mg three times a day.

The following examples are provided to further illustrate details for the preparation and use of the compounds of the present invention. The examples are not intended to be limitations on the scope  
30 of the instant invention in any way, and they should not be so construed. Furthermore, the compounds described in the following examples are not to be construed as forming the only genus that is considered as the invention, and any combination of the compounds or their moieties may itself form a genus. Those skilled in the art will readily understand that  
35 known variations of the conditions and processes of the following


preparative procedures can be used to prepare these compounds. All temperatures are in degrees Celsius unless noted otherwise.

Abbreviations: aq is aqueous; Ac represents acetyl; ACN is acetonitrile; Bn represents benzyl; DMF is dimethyl formamide; DMSO is dimethyl sulfoxide; Et represents ethyl; IPA is isopropyl alcohol; Me represents methyl; NaHMDS represents sodium hexamethyl disilamide; rt, RT both represent room temperature; sat represents saturated; THF is tetrahydrofuran; TLC is thin layer (SiO<sub>2</sub>) chromatography.

#### EXAMPLE 1


2,4-dioxo-4-(5-phenethylthiophen-2-yl)butanoic acid

Step A: Preparation of ethyl 2,4-dioxo-4-(5-phenethylthiophen-2-yl)butanoate AI(2)




A mixture of 2-acetyl-5-(phenylethynyl)thiophene (1.81 g, 8.02 mmol), diethyl oxalate (2.17 mL, 16 mmol), and sodium ethoxide (1.09 g, 16 mmol) in anhydrous THF (25 mL) was stirred at rt under an atmosphere of argon for 5 hr. The resultant mixture was diluted with dichloromethane, and washed successively with dilute HCl, and brine. The organic extract was dried over anhydrous magnesium sulfate, filtered, and concentrated under vacuum to provide yellow solid. Recrystallization of the solid from a mixture dichloromethane and hexane provided the title compound.

Step B: Preparation of ethyl 2,4-dioxo-4-(5-phenethylthiophen-2-yl)butanoate AI(3)



A mixture of ethyl 2,4-dioxo-4-(5-phenethylthiophen-2-yl)butanoate (195 mg, 0.597 mmol), 10% Pd/C (95 mg), and THF (5 mL) in absolute ethanol (40 mL) was stirred under a balloon of hydrogen for 2 h. The resulting mixture was filtered through a pad of Celite™, diatomaceous earth. The filtrate was concentrated under vacuum to provide the title compound.

Step C: Preparation of 2,4-dioxo-4-(5-phenethylthiophen-2-yl)butanoic acid AI(4)




A solution of ethyl 2,4-dioxo-4-(5-phenethylthiophen-2-yl)butanoate (125 mg, 0.378 mmol), aqueous sodium hydroxide (1.2 mL, 1M, 1.2 mmol), and THF (5 mL) in methanol (5 mL) was stirred at rt overnight. The resultant mixture was treated with aq HCl (1.3 mL, 1M), and concentrated under vacuum. The residue was partitioned between brine and dichloromethane. The organic extract was dried over anhydrous magnesium sulfate, filtered, and concentrated under vacuum to provide off-white solid. Recrystallization of the solid from a mixture dichloromethane and hexane provided the title compound. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.72 (d, *J* = 3.1 Hz, 1H), 7.35-7.15 (m, 5H), 6.94 (s, 1H), 6.86 (d, *J* = 3.1 Hz, 1H), 3.22 (d, *J* = 8.1 Hz, 2H), 3.03 (d, *J* = 8.1 Hz, 2H).

25

## EXAMPLE 2

2,4-dioxo-4-(5-benzyloxythiophen-2-yl)butanoic acid


Step A: Preparation of 2-acetyl-5-(benzyloxy)thiophene AI(2a)



A suspension of sodium hydride (538 mg, 22.4 mmol) in anhydrous DMSO (30 mL) was stirred at 60 °C under an atmosphere of argon for 1  
5 hr. The resultant mixture was cooled to rt, benzyl alcohol (2.32 mL, 22.40 mmol) and 2-acetyl-5-chlorothiophene (3.01 g, 18.74 mmol) was added. The mixture was heated under an atmosphere of argon at 85 °C overnight. The product mixture was concentrated under vacuum, and the residue partitioned between ethyl acetate and dilute aqueous HCl.  
10 The organic extract was washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue was subjected to column chromatography on silica gel eluting with 3% methanol in chloroform. Collection and concentration of appropriate fractions provided the title ketone.

15

Step B: Preparation of 2,4-dioxo-4-(5-benzyloxythiophen-2-yl)butanoic acid AII(4a)




The title compound was prepared using the protocol described in  
20 Example AI(4), Step A and C substituting 2-acetyl-5-(phenylethynyl)-thiophene with 2-acetyl-5-(benzyloxy)thiophene in Step A. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.75 (d, *J* = 4.6 Hz, 1H), 7.5-7.3 (m, 5H), 6.85 (s, 1H), 6.42 (d, *J* = 4.6 Hz, 1H), 5.21 (s, 2H).

25

### EXAMPLE 3


2,4-dioxo-4-[5-(3-fluorobenzyloxy)thiophen-2-yl]butanoic acid



The title compound was prepared using the protocol described in Example AII(4a), Step A - B substituting benzyl alcohol with 3-fluorobenzyl alcohol in Step A. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 8.0 (br s 1H), 7.5-7.15 (m, 4H), 6.85 (brs, 1H), 6.6 (br s, 1H), 5.3 (br s, 2H).

#### EXAMPLE 4

2,4-dioxo-4-[5-(4-fluorobenzoyloxy)thiophen-2-yl]butanoic acid




10

The title compound was prepared using the protocol described in Example AII(4a), Step A - B substituting benzyl alcohol with 4-fluorobenzyl alcohol in Step A. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 8.0 (br s 1H), 7.54 (m, 2H), 7.25 (m, 2H), 6.85 (brs, 1H), 6.6 (br s, 1H), 5.3 (br s, 2H).

15

#### EXAMPLE 5


2,4-dioxo-4-[5-(3,4-difluorobenzoyloxy)thiophen-2-yl]butanoic acid



20 The title compound was prepared using the protocol described in Example AII(4a), Step A - B substituting benzyl alcohol with 3,4-difluorobenzyl alcohol in Step A. <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.79 (d, *J* = 4.4 Hz, 1H), 7.45-7.25 (m, 3H), 6.92 (s, 1H), 6.53 (d, *J* = 4.4 Hz, 1H), 5.24 (s, 2H).

## EXAMPLE 6

2,4-dioxo-4-[5-(pyridin-2-ylmethoxy)thiophen-2-yl]butanoic acid



5

The title compound was prepared using the protocol described in Example AII(4a), Step A - B substituting benzyl alcohol with 2-pyridylcarbinol in Step A. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 8.60 (d, *J* = 4.6 Hz, 1H), 8.07 (d, *J* = 4.6 Hz, 1H), 7.87 (ddd, *J* = 7.7, 7.7, 1.7 Hz, 1H), 7.56 (d, *J* = 7.7 Hz, 1H), 7.40 (dd, *J* = 7.7, 4.7 Hz, 1H), 6.95 (s, 1H), 6.67 (d, *J* = 4.6 Hz, 1H), 5.39 (s, 2H).


10

## EXAMPLE 7

2,4-dioxo-4-[5-(3-fluorobenzyl)thiophen-2-yl]butanoic acid

15

Step A: Preparation of (5-bromothiophen-2-yl)-(3-fluorophenyl)methanol BI(2a)



To a cold (-78 °C) solution of *n*-butyl lithium (20.8 mL, 2.5 M in hexane, 52 mmol) in anhydrous diethyl ether (100 mL) under an atmosphere of argon, 2,5-dibromothiophene (5.63 mL, 50 mmol) was added dropwise over a period of 30 min. After the reaction mixture was stirred at -78 °C for an additional 90 min, 3-fluorobenzaldehyde (5.5 mL, 52 mmol) was added over a period of 15 min. The resultant mixture was allowed to warm to rt over a period of 2.5 h. The resultant solution was diluted with


20

25




dichloromethane, and neutralized with dilute HCl. The organic extract was washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under vacuum to provide the title compound as brown oil. The oil was used in the following step without further  
5 purification.

Step B: Preparation of 2-bromo-5-(3-fluorobenzyl)thiophene BK(3a)



To a cold (0 °C) solution of (5-bromothiophen-2-yl)-(3-fluorophenyl)-  
10 methanol (4.35 g, 15.2 mmol) and triethylsilane (3.60 mL, 22.7 mmol) in dichloromethane (30 mL), boron trifluoride etherate (2.90 mL, 22.9 mmol) was added. The resultant mixture was stirred at rt for 3 h, and treated with sat. aq. sodium bicarbonate. The organic extract was washed with brine, dried over anhydrous magnesium sulfate, filtered,  
15 and concentrated under vacuum. The residue was subjected to column chromatography on silica gel eluting with hexane. Collection and concentration of appropriate fractions provide the title compound as clear colorless oil. The product was stored under argon in a freezer.


20 Step C: Preparation of 2-acetyl-5-(3-fluorobenzyl)thiophene BK(4a)



To a cold (-78 °C) solution of 2-bromo-5-(3-fluorobenzyl)thiophene (2.0 g, 7.38 mmol) in anhydrous diethyl ether (20 mL) under an atmosphere of argon, n-butyl lithium (4.8 mL, 1.6 M in hexane, 7.68 mmol) was added  
25 dropwise over a period of 15 min. After the reaction mixture was stirred at -78 °C for an additional 1 h, N-methoxy-N-methylacetamide (0.91 mL,

8.86 mmol) was added over a period of 10 min. The resultant mixture was allowed to warm to rt and stirred overnight. The resultant solution was diluted with ether, and neutralized with dilute HCl. The organic extract was washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under vacuum. The residue was subjected to column chromatography on silica gel eluting with 20% ethyl acetate in hexane. Collection and concentration of appropriate fractions provide the title compound as clear pale yellow oil.


- 10 Step D: Preparation of ethyl 2,4-dioxo-4-[5-(3-fluorobenzyl)thiophen-2-yl]butanoate BK(5a)



To a cold (-78 °C) solution of 2-acetyl-5-(3-fluorobenzyl)thiophene (315 mg, 1.34 mmol) in anhydrous THF (5 mL) under an atmosphere of argon, LDA (0.7 mL, 2 M in a mixture of heptane, THF and ethylbenzene, 1.40 mmol) was added dropwise over a period of 10 min. After the reaction mixture was stirred at -78 °C for an additional 40 min, diethyl oxalate (0.26 mL, 1.91 mmol) was added over a period of 5 min. The resultant mixture was allowed to warm to rt and stirred overnight. The resultant solution was diluted with ethyl acetate, and neutralized with dilute HCl. The organic extract was washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under vacuum. The residue was triturated with hexane. The precipitate was filtered to provide the title compound as yellow solid.

25

- Step E: Preparation of 2,4-dioxo-4-[5-(3-fluorobenzyl)thiophen-2-yl]butanoic acid BI(6a)




The title compound was prepared using the protocol described in Example AI(4), Step C substituting ethyl 2,4-dioxo-4-(5-phenethylthiophen-2-yl)butanoate with ethyl 2,4-dioxo-4-[5-(3-fluorobenzyl)thiophen-2-yl]butanoate. The product was recrystallized from a mixture of ether and hexane.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.75 (d,  $J = 4.1$  Hz, 1H), 7.35-7.25 (m, 2H), 7.05-6.90 (m, 4H), 4.20 (s, 2H).

#### EXAMPLE 8

10


2,4-dioxo-4-[5-(4-fluorobenzyl)thiophen-2-yl]butanoic acid



The title compound was prepared using the protocol described in Example BI(6a), Step A - E substituting 3-fluorobenzaldehyde with 4-fluoro-benzaldehyde in Step A.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.74 (d,  $J = 3.8$  Hz, 1H), 7.21 (m, 2H), 7.03 (m, 2H), 6.91 (m, 2H), 4.18 (s, 2H).

#### EXAMPLE 9

20 2,4-dioxo-4-[5-(3-chlorobenzyl)thiophen-2-yl]butanoic acid




The title compound was prepared using the protocol described in Example BI(6a), Step A - E substituting 3-fluorobenzaldehyde with 3-chloro-benzaldehyde in Step A.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.74 (d,  $J = 4.0$  Hz, 1H), 7.3-7.2 (m, 3H), 7.14 (m, 1H), 6.92 (m, 2H), 4.18 (s, 2H).

5

## EXAMPLE 10

2,4-dioxo-4-(5-benzylthiophen-2-yl)butanoic acid




10 The title compound was prepared using the protocol described in Example BI(6a), Step A - E substituting 3-fluorobenzaldehyde with benzaldehyde in Step A.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.74 (d,  $J = 3.9$  Hz, 1H), 7.38-7.22 (m, 5H), 6.91 (m, 2H), 4.21 (s, 2H).

15

## EXAMPLE 11

2,4-dioxo-4-(5-phenylsulfanyltiophen-2-yl)butanoic acid


Step A: Preparation of 2-acetyl-5-phenylsufanyltiophene BII(2)



20

A mixture of thiophenol, sodium salt (718 mg, 5.43 mmol) and 2-acetyl-5-bromothiophene (1.0 g, 4.88 mmol) in acetone (10 mL) was stirred at rt under an atmosphere of argon overnight. The resultant mixture was concentrated under vacuum. The residue was subjected to column chromatography on silica gel eluting with chloroform. Collection and  
25 concentration of appropriate fractions provided the title ketone.


Step B: Preparation of 2,4-dioxo-4-(5-phenylsulfanylthiophen-2-yl)butanoic acid BII(4)




5 The title compound was prepared using the protocol described in Example AI(4), Step A and C substituting 2-acetyl-5-(phenylethynyl)-thiophene with 2-acetyl-5-phenylsulfanylthiophene in Step A. The product was recrystallized from a mixture of ether and hexane. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.73 (d, *J* = 4.0 Hz, 1H), 7.48 (m, 2H), 7.38 (m, 3H), 7.08 (d, *J* = 4.0 Hz, 1H), 6.88 (s, 1H).

## EXAMPLE 12

2,4-dioxo-4-[5-(3-fluorobenzyl)thiophen-3-yl]butanoic acid




Step A: Preparation of (4-bromothiophen-2-yl)-(3-fluorophenyl)methanol CH(2a)




The title compound was prepared using the protocol described in Example BI(6a), Step A substituting 2,5-dibromothiophene with 2,4-dibromothiophene.

## Step B: Preparation of 4-bromo-2-(3-fluorobenzyl)thiophene Cl(3a)



To a cold (0 °C) solution of (5-bromothiophen-2-yl)-(3-fluorophenyl)-methanol (3.78 g, 13.2 mmol) and triethylsilane (8.4 mL, 52.7 mmol) in  
5 dichloromethane (60 mL), boron trifluoride etherate (2.49 mL, 19.8 mmol) was added. The resultant mixture was stirred at rt for 2 h, and treated with sat. aq. sodium bicarbonate. The organic extract was washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under vacuum. The residue was subjected to column  
10 chromatography on silica gel eluting with hexane. Collection and concentration of appropriate fractions provide the title compound as clear colorless oil. The product was stored under argon in a freezer.


## Step C: Preparation of 2,4-dioxo-4-[5-(3-fluorobenzyl)thiophen-3-yl]butanoic acid Cl(6a)



The title compound was prepared using the protocol described in Example BI(6a), Step C - E substituting 2-bromo-5-(3-fluorobenzyl)-thiophene with 4-bromo-2-(3-fluorobenzyl)thiophene in Step C. <sup>1</sup>H NMR  
20 (CDCl<sub>3</sub>) δ 8.08 (d, *J* = 1.5 Hz, 1H), 7.35-7.25 (m, 3H), 7.05-6.92 (m, 2H), 6.90 (s, 1H), 4.15 (s, 2H).

## EXAMPLE 13


25 2,4-dioxo-4-[5-(4-fluorobenzyl)thiophen-3-yl]butanoic acid



The title compound was prepared using the protocol described in Example CI(6a), Step A - C substituting 3-fluorobenzaldehyde with 4-fluoro-benzaldehyde in Step A. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.07 (d, *J* = 1.5 Hz, 1H), 7.26-7.18 (m, 3H), 7.05-6.92 (m, 2H), 6.89 (s, 1H), 4.13 (s, 2H).

#### EXAMPLE 14


2,4-dioxo-4-[5-(3-chlorobenzyl)thiophen-3-yl]butanoic acid



The title compound was prepared using the protocol described in Example CI(6a), Step A - C substituting 3-fluorobenzaldehyde with 3-chloro-benzaldehyde in Step A. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.09 (br s, 1H), 7.28-7.22 (m, 4H), 7.14 (m, 1H), 6.90 (s, 1H), 4.13 (s, 2H).

#### EXAMPLE 15

2,4-dioxo-4-(5-benzylthiophen-3-yl)butanoic acid



The title compound was prepared using the protocol described in Example CI(6a), Step A - C substituting 3-fluorobenzaldehyde with


benzaldehyde in Step A.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.07 (d,  $J = 1.3$  Hz, 1H), 7.36-7.22 (m, 6H), 6.89 (s, 1H), 4.16 (s, 2H).

### EXAMPLE 16

5


2,4-dioxo-4-(2-phenylsulfanylthiophen-4-yl)butanoic acid

Step A: Preparation of 2-phenylsulfanyl-4-bromothiophene CII(1)



- 10 To a cold ( $-78$  °C) solution of n-butyl lithium (10.4 mL, 2.5 M in hexane, 26 mmol) in anhydrous diethyl ether (100 mL) under an atmosphere of argon, 2,4-dibromothiophene (2.81 mL, 25 mmol) was added dropwise over a period of 15 min. After the reaction mixture was stirred at  $-78$  °C for an additional 15 min, a solution of diphenyl disulfide (5.68 g, 52
- 15 mmol) in ether (50 mL) was added over a period of 15 min. The resultant mixture was allowed to warm to rt and stirred at rt overnight. The resultant solution was diluted with ether, and washed successively with aq. NaOH, and brine. The organic extract was dried over anhydrous magnesium sulfate, filtered, and concentrated under vacuum. The
- 20 residue was subjected to column chromatography on silica gel eluting with hexane. Collection and concentration of appropriate fractions provided the title compound.

Step B: Preparation of 4-acetyl-2-phenylsulfanylthiophene CII(2)




25



To a cold (-78 °C) solution of 2-phenylsulfanyl-4-bromothiophene (2.28 g, 8.4 mmol) in anhydrous diethyl ether (20 mL) under an atmosphere of argon, n-butyl lithium (5.78 mL, 1.6 M in hexane, 9.25 mmol) was added dropwise over a period of 5 min. After the reaction mixture was stirred at -78 °C for an additional 1 h, N-methoxy-N-methylacetamide (1.03 mL, 10 mmol) was added over a period of 5 min. The resultant mixture was allowed to warm to rt and stirred overnight. The resultant solution was diluted with ether, and neutralized with dilute HCl. The organic extract was washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under vacuum. The residue was subjected to column chromatography on silica gel eluting with 20% ethyl acetate in hexane. Collection and concentration of appropriate fractions provide the title compound as clear pale yellow oil.

Step C: 2,4-dioxo-4-(2-phenylsulfanylthiophen-4-yl)butanoic acid  
CII(4)




The title compound was prepared using the protocol described in Example AI(4), Step A and C substituting 2-acetyl-5-(phenylethynyl)-thiophene with 4-acetyl-2-phenylsulfanylthiophene in Step A. The product was recrystallized from a mixture of ether and hexane. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.27 (d, *J* = 1.5 Hz, 1H), 7.68 (d, *J* = 1.5 Hz, 1H), 7.34-7.24 (m, 5H), 6.93 (s, 1H).

25

## EXAMPLE 17


2,4-dioxo-4-[2-(3-fluorobenzyl)thiophen-3-yl]butanoic acid



- The title compound was prepared using the protocol described in Example BK(6a), Step A - E substituting 2,5-dibromothiophene with 1,2-dibromothiophene in Step A.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.42 (d,  $J=5.5$  Hz, 1H), 7.32-7.24 (m, 1H), 7.20 (dd,  $J=5.5$ , 1.1 Hz, 1H), 7.05 (br d,  $J=7.5$  Hz, 1H), 6.98-6.92 (m, 3H), 4.57 (s, 2H).

#### EXAMPLE 18


- 2,4-dioxo-4-[2-(4-fluorobenzyl)thiophen-3-yl]butanoic acid



- The title compound was prepared using the protocol described in Example BI(6a), Step A - E substituting 2,5-dibromothiophene with 1,2-dibromothiophene, and 3-fluorobenzaldehyde with 4-fluorobenzaldehyde in Step A.  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  7.62 (br d, 1H), 7.47 (br d, 1H), 7.35 (m, 2H), 7.15 (m, 2H), 6.83 (br s, 1H), 4.55 (s, 2H).

#### EXAMPLE 19

- 2,4-dioxo-4-[2-(3-chlorobenzyl)thiophen-3-yl]butanoic acid




The title compound was prepared using the protocol described in Example BI(6a), Step A - E substituting 2,5-dibromothiophene with 1,2-dibromothiophene, and 3-fluorobenzaldehyde with 3-chlorobenzaldehyde in Step A. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 7.42 (br d, 1H), 7.3-7.1 (m, 5H), 6.92 (br s, 1H), 4.55 (s, 2H).

#### EXAMPLE 20


2,4-dioxo-4-[5-(benzyloxy-phenylmethyl)thiophen-2-yl]butanoic acid

Step A: Preparation of (5-bromothiophen-2-yl)-(phenyl)methanol  
CI(2d)



The title compound was prepared using the protocol described in Example BI(6a), Step A substituting 3-fluorobenzaldehyde with benzaldehyde. Without further purification, the alcohol was used in the following step.


Step B: Preparation of 5-(benzyloxy-phenylmethyl)-2-bromothiophene EI(1a)



A suspension of sodium hydride (147 mg, 6 mmol) in anhydrous DMSO (20 mL) was stirred at 60 °C under an atmosphere of argon for 1 hr. The resultant mixture was cooled to rt, (5-bromothiophen-2-yl)-(phenyl)-  
 5 methanol (1.5 g, 5.57 mmol) was added. After stirring for 10 min., benzyl bromide (0.8 mL, 6.68 mmol) was added. The mixture was stirred at rt under an atmosphere of argon overnight. The product mixture was concentrated under vacuum, and the residue partitioned between ethyl ether and dilute aqueous HCl. The organic extract was washed with  
 10 brine, dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue was subjected to column chromatography on silica gel eluting with 5% ethyl acetate in hexane. Collection and concentration of appropriate fractions provided the title compound.

15

Step C: Preparation of 2,4-dioxo-4-[5-(benzyloxy-phenylmethyl)thiophen-2-yl]butanoic acid EI(5a)




The title compound was prepared using the protocol described in  
 20 Example BI(6a), Step C - E substituting 2-bromo-5-(3-fluorobenzyl)-thiophene with 5-(benzyloxy-phenylmethyl)-2-bromothiophene in Step C.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.71 (d,  $J = 4.0$  Hz, 1H), 7.5-7.3 (m, 9H), 6.94 (s, 1H), 6.86 (d,  $J = 4.0$  Hz, 1H), 5.62 (s, 2H), 4.63 (d,  $J = 12.1$  Hz, 1H), 4.53 (d,  $J = 12.1$  Hz, 1H).

5

## EXAMPLE 21



2,4-dioxo-4-[5-(phenoxy-phenylmethyl)thiophen-2-yl]butanoic acid


The title compound was prepared using the protocol described in

- 10 Example EI(5a), Step A - C substituting benzyl bromide with diphenyl iodonium chloride in Step B.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.73 (d,  $J = 4.0$  Hz, 1H), 7.5-7.2 (m, 7H), 7.01 (d,  $J = 4.0$  Hz, 1H), 6.94 (s, 1H), 7.00-6.95 (m, 3H), 6.41 (s, 1H).

15

## EXAMPLE 22

2,4-dioxo-4-[5-(methoxy-phenylmethyl)thiophen-2-yl]butanoic acid



The title compound was prepared using the protocol described in


- 20 Example EI(5a), Step A - C substituting benzyl bromide with methyl iodide in Step B.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.71 (d,  $J = 4.0$  Hz, 1H), 7.42 (m, 7H), 6.94 (s, 1H), 6.92 (d,  $J = 4.0$  Hz, 1H), 3.42 (s, 3H).

## EXAMPLE 23

25

## 2,4-dioxo-4-(5-dibenzylaminothiophen-2-yl)butanoic acid

Step A: Preparation of 2-acetyl-5-aminothiophene hydrochloride FI(2)




5

A mixture of 2-acetyl-5-nitrothiophene (5.00 g, 29.2 mmol), and 5% Pt<sub>2</sub>S/C (3 g) in methanol (120 mL) was stirred under a balloon of hydrogen overnight at rt. To the resulting mixture, an ethanolic solution of hydrogen chloride gas was added (final pH ~ 2), and the solution was filtered through a pad of Celite. The filtrate was concentrated under vacuum to provide the title compound.

10

Step B: Preparation of 2-acetyl-5-dibenzylaminothiophene FI(3a)




A mixture of 2-acetyl-5-aminothiophene hydrochloride (700 mg, 3.94 mmol), benzyl bromide (0.94 mL, 7.88 mmol), and diisopropylethylamine (2.4 mL, 13.8 mmol) in acetonitrile (15 mL) was stirred at 60 °C for 7 days. The resulting mixture was concentrated under vacuum. The residue was subjected to column chromatography on silica gel eluting with chloroform – chloroform saturated with ammonia gradient. Collection and concentration of appropriate fractions provided the title compound as red oil.

20

Step C: Preparation of 2,4-dioxo-4-(5-dibenzylaminothiophen-2-yl)butanoic acid FI(5a)

25




The title compound was prepared using the protocol described in Example AI(4), Step A and C substituting 2-acetyl-5-(phenylethynyl)-thiophene with 2-acetyl-5-dibenzylaminothiophene in Step A. The  
 5 product was purified by HPLC on C-18 stationary phase. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 7.93 (d, *J* = 4.8 Hz, 1H), 7.40-7.25 (m, 10H), 6.79 (s, 1H), 6.27 (d, *J* = 4.8 Hz, 1H), 4.81 (s, 4H).

#### EXAMPLE 24

10


2,4-dioxo-4-(5-benzylaminothiophen-2-yl)butanoic acid

Step A: Preparation of 2-acetyl-5-benzylaminothiophene FI(3b)



15 A mixture of 2-acetyl-5-aminothiophene hydrochloride (700 mg, 3.94 mmol), benzyl bromide (0.47 mL, 3.94 mmol), and diisopropylethylamine (1.72 mL, 9.85 mmol) in acetonitrile (15 mL) was stirred at 60 °C for 4 days. The resulting mixture was concentrated under vacuum. The residue was subjected to column chromatography on silica gel eluting  
 20 with chloroform – chloroform saturated with ammonia gradient. Collection and concentration of appropriate fractions provided the title compound.

Step B: Preparation of 2,4-dioxo-4-(5-benzylaminothiophen-2-yl)butanoic acid FI(5b)




The title compound was prepared using the protocol described in  
 5 Example AI(4), Step A and C substituting 2-acetyl-5-(phenylethynyl)-thiophene with 2-acetyl-5-benzylaminothiophene in Step A. The product was purified by HPLC on C-18 stationary phase. <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.70 (d, *J* = 4.6 Hz, 1H), 7.40-7.25 (m, 5H), 6.79 (s, 1H), 6.14 (d, *J* = 4.6 Hz, 1H), 4.86 (s, 2H).

10

#### EXAMPLE 25

2,4-dioxo-4-(5-diallylaminothiophen-2-yl)butanoic acid


15 Step A: Preparation of 2-acetyl-5-diallylaminothiophene FI(3c)



A mixture of 2-acetyl-5-aminothiophene hydrochloride (1.5 g, 8.44 mmol), allyl bromide (7.30 mL, 84.4 mmol), and diisopropylethylamine (6.5 mL, 37.3 mmol) in acetonitrile (10 mL) was stirred at 60 °C for 3  
 20 days. The resulting mixture was concentrated under vacuum. The residue was subjected to column chromatography on silica-gel eluting with 40% ethyl acetate in hexane. Collection and concentration of appropriate fractions provided the title compound as orange oil.



Step B: Preparation of 2,4-dioxo-4-(5-diallylaminothiophen-2-yl)butanoic acid FI(5c)




The title compound was prepared using the protocol described in Example AI(4), Step A and C substituting 2-acetyl-5-(phenylethynyl)-thiophene with 2-acetyl-5-diallylaminothiophene in Step A. The product was purified by HPLC on C-18 stationary phase. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.67 (d, *J* = 4.6 Hz, 1H), 6.76 (s, 1H), 6.06 (d, *J* = 4.6 Hz, 1H), 5.85 (m, 2H), 5.3 (m, 4H), 4.05 (m, 4H).

10

#### EXAMPLE 26

2,4-dioxo-4-(5-di-n-propylaminothiophen-2-yl)butanoic acid


Step A: Preparation of 2-acetyl-5-di-n-propylaminothiophene FI(3d)



A mixture of 2-acetyl-5-diallylaminothiophene (200 mg, 0.904 mmol) and 5% Pd/C (200 mg) in methanol (10 mL) was stirred under a balloon of hydrogen for 3 h. The resulting mixture was filtered through a pad of Celite™, diatomaceous earth. The filtrate was concentrated under vacuum to provide the title compound.

20

Step B: Preparation of 2,4-dioxo-4-(5-di-n-propylaminothiophen-2-yl)butanoic acid FI(5d)




The title compound was prepared using the protocol described in Example AK(4), Step A and C substituting 2-acetyl-5-(phenylethynyl)-thiophene with 2-acetyl-5-di-n-propylaminothiophene in Step A. The  
 5 product was purified by HPLC on C-18 stationary phase. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 7.95 (d, *J* = 4.8 Hz, 1H), 6.81 (s, 1H), 6.19 (d, *J* = 4.8 Hz, 1H), 3.38 (t, *J* = 7.5 Hz, 4H), 1.62 (h, *J* = 7.5 Hz, 4H), 0.89 (d, *J* = 7.5 Hz, 6H),

#### EXAMPLE 27

10

2,4-dioxo-4-[5-(di-4-fluorobenzylamino)thiophen-2-yl]butanoic acid

Step A: Preparation of 2-acetyl-5-(di-4-fluorobenzylamino)thiophene FI(3e)




15

A mixture of 2-acetyl-5-aminothiophene hydrochloride (600 mg, 3.38 mmol), 4-fluorobenzyl bromide (0.92 mL, 7.43 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (2.42 g, 7.43 mmol) in DMF (10 mL) was stirred at rt for 2 days. The resulting mixture was concentrated under vacuum. The residue was treated with  
 20 a mixture of chloroform and aq HCl. After stirring at rt for 1 h, the pH of the mixture was adjusted to ~8. The organic extract was washed with brine, dried over sodium sulfate, filtered and concentrated under vacuum. The residue was subjected to column chromatography on

silica gel eluting with 40% ethyl acetate in hexane. Collection and concentration of appropriate fractions provided the title compound.

- 5 Step B: Preparation of 2,4-dioxo-4-[5-(di-4-fluorobenzylamino)thiophen-2-yl]butanoic acid FK(5e)




- The title compound was prepared using the protocol described in Example AI(4), Step A and C substituting 2-acetyl-5-(phenylethynyl)-thiophene with 2-acetyl-5-(di-4-fluorobenzylamino)thiophene in Step A.
- 10 <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.66 (d, *J* = 4.6 Hz, 1H), 7.2-7.0 (m, 8H), 6.78 (s, 1H), 6.14 (d, *J* = 4.6 Hz, 1H), 4.59 (s, 4H).

### EXAMPLE 28

- 15 2,4-dioxo-4-[5-(N-benzyl-N-methylamino)thiophen-2-yl]butanoic acid


Step A: Preparation of 2-acetyl-5-(N-benzyl-N-methylamino)thiophene FII(1a)



- 20 A solution of cesium carbonate (3.25 g, 10 mmol), N-methyl-N-benzylamine (2.58 mL, 20 mmol) and 2-acetyl-5-chlorothiophene (1.61 g, 10 mmol) in DMF (20 mL) was stirred at 60 °C under an atmosphere of argon for 9 days. The product mixture was concentrated under vacuum, and the residue was treated with a mixture of ethyl ether and dilute

aqueous HCl. After stirring at rt for 1 h, pH of the solution was adjusted to ~8 with sat. aq. NaHCO<sub>3</sub>, and organic extract was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was subjected to column chromatography on silica gel eluting with 30% ethyl acetate in hexane. Collection and concentration of appropriate fractions provided the title ketone.

Step B: Preparation of 2,4-dioxo-4-[5-(N-benzyl-N-methylamino)thiophen-2-yl]butanoic acid FII(3a)




The title compound was prepared using the protocol described in Example AI(4), Step A and C substituting 2-acetyl-5-(phenylethynyl)-thiophene with 2-acetyl-5-(benzylmethylamino)thiophene in Step A. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.70 (d, *J* = 4.6 Hz, 1H), 7.4-7.2 (m, 5H), 6.77 (br s, 1H), 6.10 (d, *J* = 4.6 Hz, 1H), 4.62 (s, 2H), 3.15 (s, 3H).

#### EXAMPLE 29


2,4-dioxo-4-(5-piperidin-1-yl-thiophen-2-yl)butanoic acid

Step A: Preparation of 2-acetyl-5-piperidin-1-yl-thiophene FII(2b)



The title compound was prepared using the protocol described in Example FII(3a), Step A and C substituting N-methyl-N-benzylamine with piperidine in Step A, and using DMSO as solvent.

Step B: Preparation of 2,4-dioxo-4-(5-piperidin-1-yl-thiophen-2-yl)butanoic acid FII(3b)



The title compound was prepared using the protocol described in Example AK(4), Step A and C substituting 2-acetyl-5-(phenylethynyl)-thiophene with 2-acetyl-5-piperidin-1-yl-thiophene in Step A. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.70 (d, *J* = 4.8 Hz, 1H), 6.77 (br s, 1H), 6.13 (d, *J* = 4.6 Hz, 1H), 3.41 (t, *J* = 5.7 Hz, 4H), 1.7 (m, 6H).


10

## EXAMPLE 30

2,4-dioxo-4-[5-(benzylbenzenesulfonylamino)thiophen-2-yl]butanoic acid

Step A: Preparation of 2-acetyl-5-(benzenesulfonylamino)thiophene FIII(1)


15



A solution of 2-amino-5-acetylthiophene hydrochloride (0.75 g, 4.22 mmol), benzenesulfonyl chloride (0.7 mL, 5.49 mmol) in pyridine (15 mL) was stirred at 70 °C under an atmosphere of argon for 1.5 h. The product mixture was concentrated under vacuum, and the residue was partitioned between ethyl acetate and aq. HCl. The organic extract was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was subjected to column chromatography on silica gel eluting with 50% ethyl acetate in hexane.


Collection and concentration of appropriate fractions provided the title sulfonamide.

5      Step B:      Preparation of 2-acetyl-5-(benzylbenzenesulfonylamino)thiophene FIII(2)



To a solution of 2-acetyl-5-(benzenesulfonylamino)thiophene (0.192 g, 0.682 mmol) in DMSO (11.5 mL), a solution of NaHMDS (0.72 mL, 1M) in THF was added. The resultant deep red solution was stirred at rt for 2.5 h, and treated with benzyl bromide (89.2  $\mu$ L, 0.75 mmol), and stirred at rt overnight. The product mixture was concentrated under vacuum, and the residue was partitioned between dichloromethane and aq. HCl. The organic extract was washed with brine, dried over anhydrous  $\text{MgSO}_4$ , filtered and concentrated under vacuum. The residue was subjected to column chromatography on silica gel eluting with 40% ethyl acetate in hexane. Collection and concentration of appropriate fractions provided the title ketone.

20      Step C:      Preparation of 2,4-dioxo-4-[5-(benzylbenzenesulfonylamino)thiophen-2-yl]butanoic acid FIII(4)




The title compound was prepared using the protocol described in Example AI(4), Step A and C substituting 2-acetyl-5-(phenylethynyl)-thiophene with 2-acetyl-5-(benzylbenzenesulfonylamino)thiophene in Step A. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.76 (d, *J* = 4.5 Hz, 1H), 7.7-7.5 (m, 5H), 7.3 (m, 5H), 6.83 (br s, 1H), 6.82 (d, *J* = 4.5 Hz, 1H), 4.83 (s, 4H).

## EXAMPLE 31

2,4-dioxo-4-(2-dibenzylaminothiazol-5-yl)butanoic acid


10

Step A: Preparation of 1,1-dibenzylthiourea GI(1a)




A mixture of dibenzylamine (9.6 mL, 50 mmol) and tert-butyl isothiocyanate (6.34 mL, 50 mmol) in hexane (50 mL) was stirred at rt overnight. The white precipitate was isolated by filtration, and was treated with concentrated hydrochloric acid (25 mL) at 100 °C for 1.5 h. The product mixture was concentrated under vacuum. The residue was treated with 10% aq. NaHCO<sub>3</sub>. The white solid precipitated was obtained by filtration, and recrystallized from a mixture of chloroform and hexane. Filtration provided the title compound as white powder.

Step B: Preparation of 1,1-dibenzyl-3-dimethylaminomethylenethiourea GI(2a)



A mixture of 1,1-dibenzylthiourea (4.0 g, 15.6 mmol) and N,N-dimethylformamide dimethyl acetal (20 mL) was heated at 100 °C for 1 h. The reaction mixture was concentrated, and the residue was  
 5 recrystallized from a mixture of chloroform and hexane. Filtration of the white solid provide the title compound.


Step C: Preparation of 2-dibenzylamino-5-acetylthiazole GI(3a)



10 A solution of 1,1-dibenzyl-3-dimethylaminomethylenethiourea (1.8 g, 5.78 mmol) and bromoacetone (0.93 g, 5.78 mmol) in acetone (25 mL) was stirred in the dark for 3 days. The resultant mixture was concentrated under vacuum, and the residue partitioned between toluene and aq.  
 sodium bicarbonate. The organic extract was washed with brine, dried  
 15 over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under vacuum. The residue was recrystallized from a mixture ethyl acetate and hexane to provide the title compound as light yellow solid.

20 Step D: Preparation of 2,4-dioxo-4-(2-dibenzylaminothiazol-5-yl)butanoic acid GI(5a)






The title compound was prepared using the protocol described in Example AI(4), Step A and C substituting 2-acetyl-5-(phenylethynyl)-thiophene with 2-dibenzylamino-5-acetylthiazole in Step A. The product  
 5 was purified by recrystallization from toluene.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.19 (s, 1H), 7.40-7.20 (m, 10H), 6.81 (s, 1H), 4.76 (s, 4H).

### EXAMPLE 32

10 2,4-dioxo-4-(2-benzylaminothiazol-5-yl)butanoic acid


Step A: Preparation of 1-benzyl-3-dimethylaminomethylenethiourea  
 GI(2b)



15 A mixture of 1-benzylthiourea (8.3 g, 50 mmol) and N,N-dimethyl-formamide dimethyl acetal (25 mL) was heated at 100 °C for 1 h. The reaction mixture was concentrated, and the residue was recrystallized from a mixture of chloroform and hexane. Filtration of the white solid provide the title compound.


20

Step B: Preparation of 2-benzylamino-5-acetylthiazole GI(3b)



A solution of 1-benzyl-3-dimethylaminomethylenethiourea (4.0 g, 18 mmol) and bromoacetone (2.5 g, 18.3 mmol) in acetone (75 mL) was stirred in the dark for 3 days. The white precipitated was isolated by  
 5 filtration and dissolved in chloroform. The organic solution was washed successively with aq. NaHCO<sub>3</sub>, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under vacuum. The residue was recrystallized from a mixture dichloromethane and hexane to provide the title compound.

10 Step C: Preparation of 2,4-dioxo-4-(2-benzylaminothiazol-5-yl)butanoic acid GI(5b)




The title compound was prepared using the protocol described in Example AI(4), Step A and C substituting 2-acetyl-5-(phenylethynyl)-  
 15 thiophene with 2-benzylamino-5-acetylthiazole in Step A. The product was purified by recrystallization from a mixture of THF and hexane. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 9.50 (br s, 1H), 8.39 (s, 1H), 7.40-7.20 (m, 5H), 6.88 (s, 1H), 4.57 (d, *J*=5.4 Hz, 2H).

20

## EXAMPLE 33

2,4-dioxo-4-(2-N-benzyl-N-methylaminothiazol-5-yl)butanoic acid


25 Step A: Preparation of 2-N-benzyl-N-methylamino-5-acetylthiazole GI(3c)



The title compound was prepared using the protocol described in Example GI(5a), Step A – C substituting N,N-dibenzylamine with N-benzyl-N-methylamine in Step A.

5

Step B: Preparation of 2,4-dioxo-4-(2-N-benzyl-N-methylaminothiazol-5-yl)butanoic acid GI(5c)




The title compound was prepared using the protocol described in Example AI(4), Step A and C substituting 2-acetyl-5-(phenylethynyl)-thiophene with 2-N-benzyl-N-methylamino-5-acetylthiazole in Step A. The product was purified by recrystallization from toluene. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.01 (s, 1H), 7.40-7.20 (m, 5H), 6.78 (s, 1H), 4.82 (s, 2H), 3.15 (s, 3H).

15

#### EXAMPLE 34

2,4-dioxo-4-(2-dibenzylaminothiazol-4-yl)butanoic acid


20 Step A: Preparation of 2-dibenzylamino-4-acetylthiazole GII(3)



A suspension of 1,1-dibenzylthiourea (3.05 g, 11.9 mmol) in absolute ethanol (40 mL) was treated with 1-bromo-2,3-butanedione (2.06 g, 12.5 mmol). The mixture was heated under reflux for 2 h. The resultant mixture was cooled to 0 °C, and white solid precipitated. The white solid was dissolved in ethyl acetate, and washed with sat. aq. NaHCO<sub>3</sub>. The organic extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under vacuum. The residue solidified upon standing to provide the title compound.

10

Step D: Preparation of 2,4-dioxo-4-(2-dibenzylaminothiazol-4-yl)butanoic acid GI(5)



The title compound was prepared using the protocol described in Example AI(4), Step A and C substituting 2-acetyl-5-(phenylethynyl)-thiophene with 2-dibenzylamino-4-acetylthiazole in Step A. The product was purified by recrystallization from a mixture of ether and hexane as orange needles. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.56 (s, 1H), 7.40-7.20 (m, 11H), 4.70 (s, 4H).

20

#### EXAMPLE 35

HIV Integrase Assay: Strand Transfer Catalyzed by Recombinant Integrase and Preintegration Complexes

Assays for the strand transfer activity of integrase were conducted according to Wolfe, A.L. et al., J. Virol. 70, 1424 (1996), and Farnet, C.M. and Bushman F.D. (1997) Cell; 88, 483 for recombinant integrase and preintegration complexes, respectively, hereby  
5 incorporated by reference for these purposes.

Representative compounds tested in the integrase assay demonstrated IC<sub>50</sub>'s less than 1 micromolar. Further, representative compounds tested in the preintegration complex assay also demonstrated IC<sub>50</sub>'s of less than 1 micromolar.

10

#### EXAMPLE 36

##### Assay for inhibition of HIV replication

Assays for the inhibition of acute HIV infection of T-lymphoid cells was conducted according to Vacca, J.P. et al., (1994),  
15 Proc. Natl. Acad. Sci. USA 91, 4906, herein incorporated by reference for these purposes.

Representative compounds tested in the present assay demonstrated IC<sub>95</sub>s of less than 10 micromolar.

20

#### EXAMPLE 37


##### Oral Composition

As a specific embodiment of an oral composition of a compound of this invention, 50 mg of a compound of the present  
25 invention is formatted with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size 0 hard gelatin capsule.

While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of  
30 illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adoptions, or modifications, as come within the scope of the following claims and their equivalents.

## WHAT IS CLAIMED:


1. A compound of structural formula (I):



or tautomers or pharmaceutically acceptable salts thereof,

5 wherein:

A is a five-membered heteroaromatic ring containing 1 sulfur atom and 0 or 1 nitrogen atoms and substituted on carbon by  $R^1$ ,  $R^2$  and  $R^8$ ; the heteroaromatic ring may optionally be fused with a phenyl ring or a C4-6 cycloalkyl ring, or with two six membered rings to form:



10

$R^1$  is selected from:

- (1) -H,
- (2) -C<sub>1-5</sub> alkyl,
- (3) -CF<sub>3</sub>,
- 15 (4) -halo,
- (5) -NO<sub>2</sub>,
- (6) -N(R<sup>4</sup>)(R<sup>5</sup>),
- (7) -R<sup>6</sup>,
- (8) -C<sub>2-5</sub> alkenyl-R<sup>3</sup>,
- 20 (9) -C<sub>2-5</sub> alkynyl-R<sup>3</sup>,
- (10) -O-R<sup>6</sup>,
- (11) -O-C<sub>1-6</sub> alkyl, and
- (12) -C(O)CH<sub>2</sub>C(O)C(O)OR<sup>7</sup>;

$R^2$  is selected from:

- (1) -H,
- (2)  $-R^3$ ,
- (3)  $-C_{1-6}$  alkyl,
- 5 (4)  $-C_{1-6}$  alkyl substituted with  $R^3$ ,
- (5)  $-O-R^6$ ,
- (6)  $-O-C_{1-6}$  alkyl- $OR^6$ ,
- (7)  $-S(O)_n-R^6$ ,
- (8)  $-C_{1-6}$  alkyl  $(OR^6)(R^4)$ ,
- 10 (9)  $-C_{1-6}$  alkyl  $(OR^4)(R^6)$ ,
- (10)  $-C_{0-6}$  alkyl- $N(R^4)(R^6)$ ,
- (11)  $-C_{1-6}$  alkyl  $S(O)_n-R^6$ ,
- (12)  $-C_{0-6}$  alkyl  $C(O)-R^6$ ,
- (13)  $-C_{0-6}$  alkyl  $C(S)-R^6$ ,
- 15 (14)  $-C_{0-6}$  alkyl  $NR^4C(O)-R^6$ , and
- (15)  $-C_{0-6}$  alkyl- $C(O)N(R^4)(R^5)$ ;

each  $R^3$  is independently selected from:

- (1) a 5 or 6 membered aromatic or heteroaromatic ring,  
 20 containing 0, 1, 2, 3, or 4 heteroatoms selected from oxygen,  
 nitrogen and sulfur, unsubstituted or substituted on a  
 nitrogen or carbon atom by 1 to 5 substituents selected from:
  - (a) halogen,
  - (b)  $C_{1-6}$  alkyl,
  - 25 (c)  $C_{1-6}$  alkyloxy-,
  - (d) phenyl,
  - (e)  $-CF_3$ ,
  - (f)  $-OCF_3$ ,
  - (g)  $-CN$ ,
  - 30 (h) hydroxy,
  - (i) phenyloxy, and

- (j) substituted phenoxy with 1, 2, or 3 substituents selected from:
- (i) halogen,
  - (ii) C<sub>1-6</sub> alkyl,
  - (iii) -CF<sub>3</sub>, and
  - (iv) hydroxy;
- (2) a 3 to 6 membered saturated ring containing 0 or 1 heteroatoms selected from oxygen, nitrogen or sulfur, unsubstituted or substituted with 0 to 5 substituents selected from:
- (a) halogen,
  - (b) C<sub>1-6</sub> alkyl,
  - (c) C<sub>1-6</sub> alkyloxy-,
  - (d) -CF<sub>3</sub>,
  - (e) -OCF<sub>3</sub>,
  - (f) -CN,
  - (g) =O, and
  - (h) hydroxy;
- (3) unsubstituted or substituted hexahydrothieno[3,4-d]imidazolyl with one or two substituents selected from:
- (a) oxo,
  - (b) halogen,
  - (c) C<sub>1-6</sub> alkyl,
  - (d) C<sub>1-6</sub> alkyloxy-,
  - (e) -CF<sub>3</sub>,
  - (f) -OCF<sub>3</sub>,
  - (g) -CN, and
  - (h) hydroxy;
- (4) a 5 or 6 membered aromatic or heteroaromatic ring, containing 0, 1, or 2 heteroatoms selected from oxygen,



nitrogen and sulfur, fused with a phenyl ring; wherein the ring system is unsubstituted or substituted on a nitrogen or carbon atom by 1 to 3 substituents selected from:

- 5
- (a) -halogen,
  - (b) -C<sub>1-6</sub> alkyl,
  - (c) -C<sub>1-6</sub> alkyloxy-,
  - (d) -CF<sub>3</sub>,
  - (e) -OCF<sub>3</sub>,
  - (f) -CN, and
  - 10 (g) -hydroxy;

- 15
- (5) a 3 to 6 membered saturated ring containing 0 or 1 heteroatoms selected from oxygen, nitrogen or sulfur, fused with a phenyl ring, unsubstituted or substituted with 1 or 2 substituents selected from:

- 20
- (a) halogen,
  - (b) C<sub>1-6</sub> alkyl,
  - (c) C<sub>1-6</sub> alkyloxy-,
  - (d) -CF<sub>3</sub>,
  - (e) -OCF<sub>3</sub>,
  - (f) -CN,
  - (g) =O, and
  - (h) hydroxy;

- 25
- (6) a 5 to 6 membered ring containing 0, 1 or 2 heteroatoms selected from oxygen, nitrogen or sulfur, containing 2 or 3 double bonds, unsubstituted or substituted with 1 or 2 substituents selected from:

- 30
- (a) halogen,
  - (b) C<sub>1-6</sub> alkyl,
  - (c) C<sub>1-6</sub> alkyloxy-,
  - (d) -CF<sub>3</sub>,
  - (e) -OCF<sub>3</sub>,

- (f) -CN,
- (g) =O, and
- (h) hydroxy;

5 each  $R^4$  is independently selected from:

- (1) -H,
- (2) -C<sub>1-3</sub> alkyl,
- (3) -CF<sub>3</sub>,
- (4) -R<sup>3</sup>,
- 10 (5) -C<sub>2-3</sub> alkenyl,
- (6) -C<sub>1-3</sub> alkyl-R<sup>3</sup>,
- (7) -C<sub>2-3</sub> alkenyl-R<sup>3</sup>,
- (8) -S(O)<sub>n</sub>-R<sup>3</sup>, and
- (9) -C(O)-R<sup>3</sup>;

15

each  $R^5$  is independently selected from:

- (1) -H,
- (2) -C<sub>1-3</sub> alkyl,
- (3) -CF<sub>3</sub>,
- 20 (4) -R<sup>3</sup>,
- (5) -C<sub>2-3</sub> alkenyl,
- (6) -C<sub>1-3</sub> alkyl-R<sup>3</sup>,
- (7) -C<sub>2-3</sub> alkenyl-R<sup>3</sup>,
- (8) -S(O)<sub>n</sub>-R<sup>3</sup>, and
- 25 (9) -C(O)-R<sup>3</sup>;

25

each  $R^6$  is independently selected from:

- (1) -C<sub>1-3</sub> alkyl-R<sup>3</sup>, and
- (2) -R<sup>3</sup>;

30

$R^7$  is selected from:

- (1) -H, and
- (2) C<sub>1-6</sub> alkyl;

R<sup>8</sup> is selected from:


- 5 (1) -H, and
- (2) C<sub>1-6</sub> alkyl-oxy-, and
- (3) C<sub>1-6</sub> alkyl-;

each n is independently selected from 0, 1 and 2, and  
10 each m is independently selected from 0, 1, and 2.


2. The compound according to Claim 1, and tautomers and pharmaceutically acceptable salts thereof, wherein:

15 A is selected from:


- (1) thienyl,
- (2) thiazolyl,
- (3)



20 (4)



(5)



R<sup>1</sup> is selected from:

- 25 (1) -H,
- (2) -CH<sub>3</sub>,
- (3) -CF<sub>3</sub>,
- (4) -halo,

- (5)  $-\text{NO}_2$ ,  
(6)  $-\text{N}(\text{R}^4)(\text{R}^5)$ ,  
(7) -phenyl,  
(8) substituted phenyl substituted with 1 or 2 substituents  
independently selected from:  
(a) halogen,  
(b)  $\text{C}_{1-6}$  alkyl,  
(c)  $\text{C}_{1-6}$  alkyloxy-,  
(d) phenyl,  
(e)  $-\text{CF}_3$ ,  
(f)  $-\text{OCF}_3$ ,  
(g)  $-\text{CN}$ ,  
(h) hydroxy,  
(i) phenyloxy, and  
(j) substituted phenyloxy with 1, 2, or 3 substituents  
selected from:  
(i) halogen,  
(ii)  $\text{C}_{1-6}$  alkyl,  
(iii)  $-\text{CF}_3$ , and  
(iv) hydroxy;  
(9) phenyl  $\text{C}_{1-3}$  alkyl-,  
(10) substituted phenyl  $\text{C}_{1-3}$  alkyl- substituted with 1 or 2  
substituents independently selected from:  
(a) halogen,  
(b)  $\text{C}_{1-6}$  alkyl,  
(c)  $\text{C}_{1-6}$  alkyloxy-,  
(d) phenyl,  
(e)  $-\text{CF}_3$ ,  
(f)  $-\text{OCF}_3$ ,  
(g)  $-\text{CN}$ ,  
(h) hydroxy,  
(i) phenyloxy, and

- (j) substituted phenyloxy with 1, 2, or 3 substituents selected from:
- (i) halogen,
  - (ii) C<sub>1-6</sub> alkyl,
  - (iii) -CF<sub>3</sub>, and
  - (iv) hydroxy;
- (11) -C<sub>2-5</sub> alkenyl-R<sup>3</sup>,
- (12) -C<sub>2-5</sub> alkynyl-R<sup>3</sup>, and
- (13) -C(O)CH<sub>2</sub>C(O)C(O)OR<sup>7</sup>;

R<sup>2</sup> is selected from:

- (1) -H,
- (2) -R<sup>3</sup>,
- (3) -C<sub>1-6</sub> alkyl,
- (4) -C<sub>1-6</sub> alkyl substituted with R<sup>3</sup>,
- (5) -O-R<sup>6</sup>,
- (6) -O-C<sub>1-6</sub> alkyl-OR<sup>6</sup>,
- (7) -S(O)n-R<sup>6</sup>,
- (8) -C<sub>1-6</sub> alkyl (OR<sup>6</sup>)(R<sup>4</sup>),
- (9) -C<sub>1-6</sub> alkyl (OR<sup>4</sup>)(R<sup>6</sup>),
- (10) -C<sub>0-6</sub> alkyl-N(R<sup>4</sup>)(R<sup>6</sup>),
- (11) -C<sub>1-6</sub> alkyl S(O)n-R<sup>6</sup>,
- (12) -C<sub>0-6</sub> alkyl C(O)-R<sup>6</sup>,
- (13) -C<sub>0-6</sub> alkyl C(S)-R<sup>6</sup>,
- (14) -C<sub>0-6</sub> alkyl NR<sup>4</sup>C(O)-R<sup>6</sup>, and
- (15) -C<sub>0-6</sub> alkyl-C(O)N(R<sup>4</sup>)(R<sup>5</sup>);

each R<sup>3</sup> is independently selected from:

- (1) phenyl;
- (2) substituted phenyl with 1, 2, or 3 substituents independently selected from:
  - (a) halogen,

- (b) C<sub>1-6</sub> alkyl,  
(c) C<sub>1-6</sub> alkyloxy-,  
(d) phenyl,  
(e) -CF<sub>3</sub>,  
5 (f) -OCF<sub>3</sub>,  
(g) -CN,  
(h) hydroxy,  
(i) phenyloxy, and  
(j) substituted phenyloxy with 1, 2, or 3 substituents  
10 selected from:  
(i) halogen,  
(ii) C<sub>1-6</sub> alkyl,  
(iii) -CF<sub>3</sub>, and  
(iv) hydroxy;  
15 (3) thienyl;  
(4) substituted thienyl substituted on a carbon atom with one or  
two substituents independently selected from:  
(a) halogen,  
(b) C<sub>1-6</sub> alkyl,  
20 (c) C<sub>1-6</sub> alkyloxy-,  
(d) phenyl,  
(e) -CF<sub>3</sub>,  
(f) -OCF<sub>3</sub>,  
(g) -CN,  
25 (h) hydroxy,  
(i) phenyloxy, and  
(j) substituted phenyloxy with 1, 2, or 3 substituents  
selected from:  
(i) halogen,  
30 (ii) C<sub>1-6</sub> alkyl,  
(iii) -CF<sub>3</sub>, and  
(iv) hydroxy;

- (5) pyridyl;
- (6) substituted pyridyl substituted on a carbon atom with one or two substituents independently selected from:
- 5 (a) halogen,  
(b) C<sub>1-6</sub> alkyl,  
(c) C<sub>1-6</sub> alkyloxy-,  
(d) phenyl,  
(e) -CF<sub>3</sub>,  
(f) -OCF<sub>3</sub>,  
10 (g) -CN,  
(h) hydroxy,  
(i) phenyloxy, and  
(j) substituted phenyloxy with 1, 2, or 3 substituents selected from:
- 15 (i) halogen,  
(ii) C<sub>1-6</sub> alkyl,  
(iii) -CF<sub>3</sub>, and  
(iv) hydroxy;
- (7) imidazolyl;
- 20 (8) substituted imidazolyl substituted on a carbon atom with one or two substituents independently selected from:
- (a) halogen,  
(b) C<sub>1-6</sub> alkyl,  
(c) C<sub>1-6</sub> alkyloxy-,  
25 (d) phenyl,  
(e) -CF<sub>3</sub>,  
(f) -OCF<sub>3</sub>,  
(g) -CN,  
(h) hydroxy,  
30 (i) phenyloxy, and  
(j) substituted phenyloxy with 1, 2, or 3 substituents selected from:
- (i) halogen,

- (ii) C<sub>1-6</sub> alkyl,
  - (iii) -CF<sub>3</sub>, and
  - (iv) hydroxy;
- (9) pyrrolyl;
- 5 (10) substituted pyrrolyl substituted on a carbon atom with one or two substituents independently selected from:
- (a) halogen,
  - (b) C<sub>1-6</sub> alkyl,
  - (c) C<sub>1-6</sub> alkyloxy-,
  - 10 (d) phenyl,
  - (e) -CF<sub>3</sub>,
  - (f) -OCF<sub>3</sub>,
  - (g) -CN,
  - (h) hydroxy,
  - 15 (i) phenyloxy, and
  - (j) substituted phenyloxy with 1, 2, or 3 substituents selected from:
    - (i) halogen,
    - (ii) C<sub>1-6</sub> alkyl,
    - 20 (iii) -CF<sub>3</sub>, and
    - (iv) hydroxy;
- (11) pyrazolyl;
- (12) substituted pyrazolyl substituted on a carbon atom with one or two substituents independently selected from:
- 25 (a) halogen,
- (b) C<sub>1-6</sub> alkyl,
- (c) C<sub>1-6</sub> alkyloxy-,
- (d) phenyl,
- (e) -CF<sub>3</sub>,
- 30 (f) -OCF<sub>3</sub>,
- (g) -CN,
- (h) hydroxy,



- (i) phenyloxy, and  
(j) substituted phenyloxy with 1, 2, or 3 substituents  
selected from:  
(i) halogen,  
5 (ii) C<sub>1-6</sub> alkyl,  
(iii) -CF<sub>3</sub>, and  
(iv) hydroxy;
- (13) C<sub>3-6</sub> cycloalkyl;  
(14) substituted C<sub>3-6</sub> cycloalkyl with 1 or 2 substituents  
10 independently selected from:  
(a) halogen,  
(b) C<sub>1-6</sub> alkyl,  
(c) C<sub>1-6</sub> alkyloxy-,  
(d) -CF<sub>3</sub>,  
15 (e) -OCF<sub>3</sub>,  
(f) -CN,  
(g) =O, and  
(h) hydroxy;
- (15) piperidinyl;  
20 (16) substituted piperidinyl substituted on a carbon atom with  
one or two substituents independently selected from:  
(a) halogen,  
(b) C<sub>1-6</sub> alkyl,  
(c) C<sub>1-6</sub> alkyloxy-,  
25 (d) -CF<sub>3</sub>,  
(e) -OCF<sub>3</sub>,  
(f) -CN,  
(g) =O, and  
(h) hydroxy;
- 30 (17) morpholinyl;  
(18) substituted morpholinyl substituted at a carbon or nitrogen  
atom with 1 or 2 independently selected from:  
(a) halogen,

- (b) C<sub>1-6</sub> alkyl,  
(c) C<sub>1-6</sub> alkyloxy-,  
(d) -CF<sub>3</sub>,  
(e) -OCF<sub>3</sub>,  
5 (f) -CN,  
(g) =O, and  
(h) hydroxy;
- (19) naphthyl,  
10 (20) substituted naphthyl with 1, 2, or 3 substituents  
independently selected from:  
(a) -halogen,  
(b) -C<sub>1-6</sub> alkyl,  
(c) -C<sub>1-6</sub> alkyloxy-,  
(d) -CF<sub>3</sub>,  
15 (e) -OCF<sub>3</sub>,  
(f) -CN, and  
(g) -hydroxy;
- (21) indolyl;  
(22) substituted indolyl substituted on a carbon atom with one or  
20 two substituents independently selected from:  
(a) -halogen,  
(b) -C<sub>1-6</sub> alkyl,  
(c) -C<sub>1-6</sub> alkyloxy-,  
(d) -CF<sub>3</sub>,  
25 (e) -OCF<sub>3</sub>,  
(f) -CN, and  
(g) -hydroxy;
- (23) C<sub>3-6</sub> cycloalkyl fused with a phenyl ring  
(24) substituted C<sub>3-6</sub> cycloalkyl fused with a phenyl ring  
30 substituted on a carbon atom with one or two substituents  
independently selected from:  
(a) halogen,

- 5
- (b)  $C_{1-6}$  alkyl,
  - (c)  $C_{1-6}$  alkyloxy-,
  - (d)  $-CF_3$ ,
  - (e)  $-OCF_3$ ,
  - (f)  $-CN$ ,
  - (g)  $=O$ , and
  - (h) hydroxy;

each  $R^4$  is independently selected from:

- 10
- (1)  $-H$ ,
  - (2)  $-C_{1-3}$  alkyl,
  - (3)  $-CF_3$ ,
  - (4)  $-R^3$ ,
  - (5)  $-C_{2-3}$  alkenyl,
  - 15 (6)  $-C_{1-3}$  alkyl- $R^3$ ,
  - (7)  $-C_{2-3}$  alkenyl- $R^3$ ,
  - (8)  $-S(O)_n-R^3$ , and
  - (9)  $-C(O)-R^3$ ;

20 each  $R^5$  is independently selected from:

- (1)  $-H$ ,
- (2)  $-C_{1-3}$  alkyl,
- (3)  $-CF_3$ ,
- (4)  $-R^3$ ,
- 25 (5)  $-C_{2-3}$  alkenyl,
- (6)  $-C_{1-3}$  alkyl- $R^3$ ,
- (7)  $-C_{2-3}$  alkenyl- $R^3$ ,
- (8)  $-S(O)_n-R^3$ , and
- (9)  $-C(O)-R^3$ ;

30

each  $R^6$  is independently selected from:

- (1)  $-C_{1-3}$  alkyl- $R^3$ , and
- (2)  $-R^3$ ;

$R^7$  is H;

5

$R^8$  is selected from hydrogen, methyl and methoxy;


each n is independently selected from 0, 1 and 2, and  
each m is independently selected from 0, 1, and 2.

10

3. The compound according to Claim 2, and tautomers  
and pharmaceutically acceptable salts thereof, wherein:


15 A is selected from:

- (1) thienyl,
- (2) thiazolyl,
- (3)



20

(4)



$R^1$  is selected from:

- (1) -H,
- (2)  $-CH_3$ ,
- 25 (3)  $-CF_3$ ,
- (4) -halo,
- (5)  $-NO_2$ ,
- (6)  $-N(R^4)(R^5)$ ,
- (7) -phenyl,

- (8) substituted phenyl substituted with 1 or 2 substituents independently selected from:
- (a) halo,
  - (b) methyl, and
  - (c) methoxy,
- (9) phenyl C<sub>1-3</sub> alkyl-,
- (10) substituted phenyl C<sub>1-3</sub> alkyl- substituted with 1 or 2 substituents independently selected from:
- (a) halo,
  - (b) methyl, and
  - (c) methoxy, and
- (11) -C<sub>2-5</sub> alkenyl-R<sup>3</sup>;

R<sup>2</sup> is selected from:

- (1) -H,
- (2) -R<sup>3</sup>,
- (3) -C<sub>1-6</sub> alkyl,
- (4) -C<sub>1-6</sub> alkyl substituted with R<sup>3</sup>,
- (5) -O-R<sup>6</sup>,
- (6) -S(O)<sub>n</sub>-R<sup>6</sup>,
- (7) -C<sub>1-6</sub> alkyl(OR<sup>6</sup>)(R<sup>4</sup>),
- (8) -C<sub>1-6</sub> alkyl(OR<sup>4</sup>)(R<sup>6</sup>),
- (9) -C<sub>0-6</sub> alkyl-N(R<sup>4</sup>)(R<sup>6</sup>),
- (10) -C<sub>1-6</sub> alkyl S(O)<sub>n</sub>-R<sup>6</sup>,
- (11) -C<sub>0-6</sub> alkyl C(O)-R<sup>6</sup>,
- (12) -C<sub>0-6</sub> alkyl NR<sup>4</sup>C(O)-R<sup>6</sup>, and
- (13) -C<sub>0-6</sub> alkyl-C(O)N(R<sup>4</sup>)(R<sup>5</sup>);

each R<sup>3</sup> is independently selected from:

- (1) phenyl;
- (2) substituted phenyl with 1, 2, or 3 substituents independently selected from:

- 5 (a) halogen,  
(b) C<sub>1-6</sub> alkyl,  
(c) C<sub>1-6</sub> alkyloxy-,  
(d) phenyl,  
(e) -CF<sub>3</sub>,  
(f) -OCF<sub>3</sub>,  
(g) -CN,  
(h) hydroxy,  
(i) phenyloxy, and  
10 (j) substituted phenyloxy with 1, 2, or 3 substituents  
selected from:  
(i) halogen,  
(ii) C<sub>1-6</sub> alkyl,  
(iii) -CF<sub>3</sub>, and  
15 (iv) hydroxy;
- (3) thienyl;  
(4) substituted thienyl substituted on a carbon atom with one or  
two substituents independently selected from:  
(a) halogen,  
20 (b) C<sub>1-6</sub> alkyl,  
(c) C<sub>1-6</sub> alkyloxy-,  
(d) phenyl,  
(e) -CF<sub>3</sub>,  
(f) -OCF<sub>3</sub>,  
25 (g) -CN,  
(h) hydroxy,  
(i) phenyloxy, and  
(j) substituted phenyloxy with 1, 2, or 3 substituents  
selected from:  
30 (i) halogen,  
(ii) C<sub>1-6</sub> alkyl,  
(iii) -CF<sub>3</sub>, and  
(iv) hydroxy;

- (5) pyridyl;
- (6) substituted pyridyl substituted on a carbon atom with one or two substituents independently selected from:
- 5 (a) halogen,
- (b) C<sub>1-6</sub> alkyl,
- (c) C<sub>1-6</sub> alkyloxy-,
- (d) phenyl,
- (e) -CF<sub>3</sub>,
- (f) -OCF<sub>3</sub>,
- 10 (g) -CN,
- (h) hydroxy,
- (i) phenyloxy, and
- (j) substituted phenyloxy with 1, 2, or 3 substituents selected from:
- 15 (i) halogen,
- (ii) C<sub>1-6</sub> alkyl,
- (iii) -CF<sub>3</sub>, and
- (iv) hydroxy;
- (7) imidazolyl;
- 20 (8) pyrrolyl;
- (9) pyrazolyl;
- (10) C<sub>3-6</sub> cycloalkyl,
- (11) substituted C<sub>3-6</sub> cycloalkyl with 1 or 2 substituents independently selected from:
- 25 (a) halogen,
- (b) C<sub>1-6</sub> alkyl,
- (c) C<sub>1-6</sub> alkyloxy-,
- (d) -CF<sub>3</sub>,
- (e) -OCF<sub>3</sub>,
- 30 (f) -CN,
- (g) =O, and
- (h) hydroxy;
- (12) piperidinyl;

- (13) substituted piperidinyl substituted on a carbon atom with one or two substituents independently selected from:
- (a) halogen,
  - (b) C<sub>1-6</sub> alkyl,
  - 5 (c) C<sub>1-6</sub> alkyloxy-,
  - (d) -CF<sub>3</sub>,
  - (e) -OCF<sub>3</sub>,
  - (f) -CN,
  - (g) =O, and
  - 10 (h) hydroxy;
- (14) morpholinyl;
- (15) naphthyl;
- (16) indolyl; and
- (17) C<sub>3-6</sub> cycloalkyl fused with a phenyl ring;

15

each R<sup>4</sup> is independently selected from:

- (1) -H,
- (2) -C<sub>1-3</sub> alkyl,
- (3) -CF<sub>3</sub>,
- 20 (4) -R<sup>3</sup>,
- (5) -C<sub>2-3</sub> alkenyl,
- (6) -C<sub>1-3</sub> alkyl-R<sup>3</sup>, and
- (7) -S(O)<sub>n</sub>-R<sup>3</sup>; and

25 each R<sup>5</sup> is independently selected from:

- (1) -H,
- (2) -C<sub>1-3</sub> alkyl,
- (3) -CF<sub>3</sub>,
- (4) -R<sup>3</sup>,
- 30 (5) -C<sub>2-3</sub> alkenyl,
- (6) -C<sub>1-3</sub> alkyl-R<sup>3</sup>,



(7)  $-C_{2-3}$  alkenyl- $R^3$ , and

(8)  $-S(O)_n-R^3$ ;

each  $R^6$  is independently selected from:

5 (1)  $-C_{1-3}$  alkyl- $R^3$ , and


(2)  $-R^3$ ;

$R^7$  is H;

10  $R^8$  is H; and

each n is independently selected from 0, 1 and 2.

15 4. The compound according to Claim 1 of structural formula:



and tautomers and pharmaceutically acceptable salts thereof, wherein:  
 $R^2$  is selected from:

20 (1)  $-H$ ,

(2)  $-R^3$ ,

(3)  $-C_{1-6}$  alkyl,

(4)  $-C_{1-6}$  alkyl substituted with  $R^3$ ,

(5)  $-O-R^6$ ,

25 (6)  $-S(O)_n-R^6$ ,

(7)  $-C_{1-6}$  alkyl  $(OR^6)(R^4)$ ,

(8)  $-C_{1-6}$  alkyl  $(OR^4)(R^6)$ ,

(9)  $-C_{0-6}$  alkyl- $N(R^4)(R^6)$ ,

(10)  $-C_{1-6}$  alkyl  $S(O)_n-R^6$ ,

- (11)  $-C_{0-6}$  alkyl  $C(O)-R^6$ ,
- (12)  $-C_{0-6}$  alkyl  $NR^4C(O)-R^6$ , and
- (13)  $-C_{0-6}$  alkyl- $C(O)N(R^4)(R^5)$ ;

5 each  $R^3$  is independently selected from:

- (1) phenyl,
- (2) substituted phenyl with 1, 2, or 3 substituents independently selected from:
  - (a) halogen selected from -F, -Cl, -Br,
  - 10 (b)  $CH_3$ ,
  - (c) methoxy-,
  - (d) phenyl,
  - (e)  $-CF_3$ ,
  - (f)  $-OCF_3$ ,
  - 15 (g)  $-CN$ ,
  - (h) hydroxy,
  - (i) phenoxy, and
  - (j) substituted phenoxy with 1, 2, or 3 substituents selected from:
    - 20 (i) halogen selected from -F, -Cl, -Br,
    - (ii)  $-CH_3$ ,
    - (iii)  $-CF_3$ , and
    - (iv) hydroxy;
- (3) thienyl,
- 25 (5) pyridyl,
- (7) imidazolyl,
- (8) pyrrolyl,
- (9) pyrazolyl,
- (10)  $C_{3-6}$  cycloalkyl,
- 30 (12) piperidiny, (14) morpholinyl,
- (15) naphthyl,
- (16) indolyl, and

(17)  $C_{3-6}$  cycloalkyl fused with a phenyl ring;

each  $R^4$  is independently selected from:

- (1) -H,
- 5 (2)  $-C_{1-3}$  alkyl,
- (3)  $-CF_3$ ,
- (4)  $-R^3$ ,
- (5)  $-C_{2-3}$  alkenyl,
- (6)  $-C_{1-3}$  alkyl- $R^3$ , and
- 10 (7)  $-S(O)_n-R^3$ ,

each  $R^5$  is independently selected from:

- (1) -H,
- (2)  $-C_{1-3}$  alkyl,
- 15 (3)  $-CF_3$ ,
- (4)  $-R^3$ ,
- (5)  $-C_{2-3}$  alkenyl,
- (6)  $-C_{1-3}$  alkyl- $R^3$ ,
- (7)  $-C_{2-3}$  alkenyl- $R^3$ , and
- 20 (8)  $-S(O)_n-R^3$ ,

each  $R^6$  is independently selected from:


- (1)  $-C_{1-3}$  alkyl- $R^3$ , and
- (2)  $-R^3$ ; and

25


each  $n$  is independently selected from 0, 1 and 2.

5. The compound according to Claim 4 selected from:


(1)




(2)




(3)




(4)




(5)




(6)




(7)



(8)




(9)




5


(10)



(11)




(12)




10


(13)



(14)




(15)




5


(16)



(17)










(18)




10

(19)







(26)



(27)




(28)



and tautomers and pharmaceutically acceptable salts thereof.

6. The compound according to Claim 1 of structural formula:



and tautomers and pharmaceutically acceptable salts thereof, wherein:

$R^2$  is selected from:

- (1)  $-H$ ,
- (2)  $-R^3$ ,



- (3)  $-C_{1-6}$  alkyl,
- (4)  $-C_{1-6}$  alkyl substituted with  $R^3$ ,
- (5)  $-O-R^6$ ,
- (6)  $-S(O)_n-R^6$ ,
- 5 (7)  $-C_{1-6}$  alkyl  $(OR^6)(R^4)$ ,
- (8)  $-C_{1-6}$  alkyl  $(OR^4)(R^6)$ ,
- (9)  $-C_{0-6}$  alkyl- $N(R^4)(R^6)$ ,
- (10)  $-C_{1-6}$  alkyl  $-S(O)_n-R^6$ ,
- (11)  $-C_{0-6}$  alkyl  $C(O)-R^6$ ,
- 10 (12)  $-C_{0-6}$  alkyl  $NR^4C(O)-R^6$ , and
- (13)  $-C_{0-6}$  alkyl  $-C(O)N(R^4)(R^5)$ ;

each  $R^3$  is independently selected from:

- (1) phenyl;
- 15 (2) substituted phenyl with 1, 2, or 3 substituents independently selected from:
  - (a) halogen selected from -F, -Cl, -Br,
  - (b)  $CH_3$ ,
  - (c) methoxy-,
  - 20 (d) phenyl,
  - (e)  $-CF_3$ ,
  - (f)  $-OCF_3$ ,
  - (g) -CN,
  - (h) hydroxy,
  - 25 (i) phenyloxy, and
  - (j) substituted phenyloxy with 1, 2, or 3 substituents selected from:
    - (i) halogen selected from -F, -Cl, -Br,
    - (ii)  $-CH_3$ ,
    - 30 (iii)  $-CF_3$ , and
    - (iv) hydroxy;
- (3) thienyl,

- (5) pyridyl,  
(7) imidazolyl,  
(8) pyrrolyl,  
(9) pyrazolyl,  
5 (10) C<sub>3-6</sub> cycloalkyl,  
(12) piperidinyl,  
(14) morpholinyl,  
(15) naphthyl,  
(16) indolyl, and  
10 (17) C<sub>3-6</sub> cycloalkyl fused with a phenyl ring;

each R<sup>4</sup> is independently selected from:

- (1) -H,  
(2) -C<sub>1-3</sub> alkyl,  
15 (3) -CF<sub>3</sub>,  
(4) -R<sup>3</sup>,  
(5) -C<sub>2-3</sub> alkenyl,  
(6) -C<sub>1-3</sub> alkyl-R<sup>3</sup>, and  
(7) -S(O)<sub>n</sub>-R<sup>3</sup>,

20

each R<sup>5</sup> is independently selected from:

- (1) -H,  
(2) -C<sub>1-3</sub> alkyl,  
(3) -CF<sub>3</sub>,  
25 (4) -R<sup>3</sup>,  
(5) -C<sub>2-3</sub> alkenyl,  
(6) -C<sub>1-3</sub> alkyl-R<sup>3</sup>,  
(7) -C<sub>2-3</sub> alkenyl-R<sup>3</sup>, and  
(8) -S(O)<sub>n</sub>-R<sup>3</sup>,

30

each R<sup>6</sup> is independently selected from:

- (1)  $-C_{1-3}$  alkyl- $R^3$ , and  
(2)  $-R^3$ ;


$R^8$  is selected from methyl and hydrogen; and

5

each  $n$  is independently selected from 0, 1 and 2.


7. The compound according to Claim 6 selected from:

(1)




10

(2)




(3)




15


(4)



(5)




(6)



, and


(7)



5

and tautomers and pharmaceutically acceptable salts thereof.

8. The compound according to Claim 1 of structural formula:



10

and tautomers and pharmaceutically acceptable salts thereof, wherein:  
 $R^2$  is selected from:

- (1)  $-H$ ,
- (2)  $-R^3$ ,
- (3)  $-C_{1-6}$  alkyl,
- (4)  $-C_{1-6}$  alkyl substituted with  $R^3$ ,
- (5)  $-O-R^6$ ,
- (6)  $-S(O)_n-R^6$ ,
- (7)  $-C_{1-6}$  alkyl  $(OR^6)(R^4)$ ,
- (8)  $-C_{1-6}$  alkyl  $(OR^4)(R^6)$ ,
- (9)  $-C_{0-6}$  alkyl- $N(R^4)(R^6)$ ,
- (10)  $-C_{1-6}$  alkyl  $S(O)_n-R^6$ ,

15

20

- (11)  $-C_{0-6}$  alkyl  $C(O)-R^6$ ,
- (12)  $-C_{0-6}$  alkyl  $NR^4C(O)-R^6$ , and
- (13)  $-C_{0-6}$  alkyl- $C(O)N(R^4)(R^5)$ ;

5 each  $R^3$  is independently selected from:

- (1) phenyl,
- (2) substituted phenyl with 1, 2, or 3 substituents independently selected from:
  - (a) halogen selected from -F, -Cl, -Br,
  - 10 (b)  $CH_3$ ,
  - (c) methoxy-,
  - (d) phenyl,
  - (e)  $-CF_3$ ,
  - (f)  $-OCF_3$ ,
  - 15 (g)  $-CN$ ,
  - (h) hydroxy,
  - (i) phenoxy, and
  - (j) substituted phenoxy with 1, 2, or 3 substituents selected from:
    - 20 (i) halogen selected from -F, -Cl, -Br,
    - (ii)  $-CH_3$ ,
    - (iii)  $-CF_3$ , and
    - (iv) hydroxy;
- (3) thienyl,
- 25 (5) pyridyl,
- (7) imidazolyl,
- (8) pyrrolyl,
- (9) pyrazolyl,
- (10)  $C_{3-6}$  cycloalkyl,
- 30 (12) piperidinyl,
- (14) morpholinyl,
- (15) naphthyl,
- (16) indolyl, and

(17)  $C_{3-6}$  cycloalkyl fused with a phenyl ring;

each  $R^4$  is independently selected from:

- (1) -H,
- 5 (2)  $-C_{1-3}$  alkyl,
- (3)  $-CF_3$ ,
- (4)  $-R^3$ ,
- (5)  $-C_{2-3}$  alkenyl,
- (6)  $-C_{1-3}$  alkyl- $R^3$ , and
- 10 (7)  $-S(O)_n-R^3$ ,

each  $R^5$  is independently selected from:

- (1) -H,
- (2)  $-C_{1-3}$  alkyl,
- 15 (3)  $-CF_3$ ,
- (4)  $-R^3$ ,
- (5)  $-C_{2-3}$  alkenyl,
- (6)  $-C_{1-3}$  alkyl- $R^3$ ,
- (7)  $-C_{2-3}$  alkenyl- $R^3$ , and
- 20 (8)  $-S(O)_n-R^3$ ,

each  $R^6$  is independently selected from:


- (1)  $-C_{1-3}$  alkyl- $R^3$ , and
- (2)  $-R^3$ ; and

25


each  $n$  is independently selected from 0, 1 and 2.

9. The compound according to Claim 8 selected from:


(1)




(2)




(3)



(4)




(5)



and tautomers and pharmaceutically acceptable salts thereof.

10. The compound according to Claim 1 of structural formula:



and tautomers and pharmaceutically acceptable salts thereof, wherein:

5  $R^2$  is selected from:

- (1)  $-H$ ,
- (2)  $-R^3$ ,
- (3)  $-C_{1-6}$  alkyl,
- (4)  $-C_{1-6}$  alkyl substituted with  $R^3$ ,
- 10 (5)  $-O-R^6$ ,
- (6)  $-S(O)_n-R^6$ ,
- (7)  $-C_{1-6}$  alkyl  $(OR^6)(R^4)$ ,
- (8)  $-C_{1-6}$  alkyl  $(OR^4)(R^6)$ ,
- (9)  $-C_{0-6}$  alkyl- $N(R^4)(R^6)$ ,
- 15 (10)  $-C_{1-6}$  alkyl  $S(O)_n-R^6$ ,
- (11)  $-C_{0-6}$  alkyl  $C(O)-R^6$ ,
- (12)  $-C_{0-6}$  alkyl  $NR^4C(O)-R^6$ , and
- (13)  $-C_{0-6}$  alkyl- $C(O)N(R^4)(R^5)$ ;

20 each  $R^3$  is independently selected from:

- (1) phenyl,
- (2) substituted phenyl with 1, 2, or 3 substituents independently selected from:
  - (a) halogen selected from  $-F$ ,  $-Cl$ ,  $-Br$ ,
  - 25 (b)  $CH_3$ ,
  - (c) methoxy-,
  - (d) phenyl,
  - (e)  $-CF_3$ ,



- (f)  $-\text{OCF}_3$ ,  
 (g)  $-\text{CN}$ ,  
 (h) hydroxy,  
 (i) phenoxy, and  
 5 (j) substituted phenoxy with 1, 2, or 3 substituents  
 selected from:  
 (i) halogen selected from  $-\text{F}$ ,  $-\text{Cl}$ ,  $-\text{Br}$ ,  
 (ii)  $-\text{CH}_3$ ,  
 (iii)  $-\text{CF}_3$ , and  
 10 (iv) hydroxy;  
 (3) thienyl,  
 (5) pyridyl,  
 (7) imidazolyl,  
 (8) pyrrolyl,  
 15 (9) pyrazolyl,  
 (10)  $\text{C}_{3-6}$  cycloalkyl,  
 (12) piperidinyl,  
 (14) morpholinyl,  
 (15) naphthyl,  
 20 (16) indolyl, and  
 (17)  $\text{C}_{3-6}$  cycloalkyl fused with a phenyl ring

each  $\text{R}^4$  is independently selected from:

- (1)  $-\text{H}$ ,  
 25 (2)  $-\text{C}_{1-3}$  alkyl,  
 (3)  $-\text{CF}_3$ ,  
 (4)  $-\text{R}^3$ ,  
 (5)  $-\text{C}_{2-3}$  alkenyl,  
 (6)  $-\text{C}_{1-3}$  alkyl- $\text{R}^3$ , and  
 30 (7)  $-\text{S}(\text{O})_n-\text{R}^3$ ,

each  $\text{R}^5$  is independently selected from:

- (1) -H,  
 (2) -C<sub>1-3</sub> alkyl,  
 (3) -CF<sub>3</sub>,  
 (4) -R<sup>3</sup>,  
 5 (5) -C<sub>2-3</sub> alkenyl,  
 (6) -C<sub>1-3</sub> alkyl-R<sup>3</sup>,  
 (7) -C<sub>2-3</sub> alkenyl-R<sup>3</sup>, and  
 (8) -S(O)<sub>n</sub>-R<sup>3</sup>,

10 each R<sup>6</sup> is independently selected from:


- (1) -C<sub>1-3</sub> alkyl-R<sup>3</sup>, and  
 (2) -R<sup>3</sup>; and

each n is independently selected from 0, 1 and 2.


15

11. The compound according to Claim 10 selected from:

(1)




(2)




20


(3)



(4)




(5)




5

(6)



, and

(7)




10

and tautomers and pharmaceutically acceptable salts thereof.


**12. The compound according to Claim 1 selected from:**

(1)




5


(2)



(3)




(4)




10


"(5)



(6)




(6)



, and

(7)



5

and tautomers and pharmaceutically acceptable salts thereof.

13. The compound according to Claim 1 selected from:

- (1) 2,4-dioxo-4-(5-phenethylthiophen-2-yl)butanoic acid,
- (2) ethyl 2,4-dioxo-4-(5-phenethylthiophen-2-yl)butanoate,
- (3) 2,4-dioxo-4-(5-benzyloxythiophen-2-yl)butanoic acid,
- (4) 2,4-dioxo-4-[5-(3-fluorobenzyloxy)thiophen-2-yl]butanoic acid,
- (5) 2,4-dioxo-4-[5-(4-fluorobenzyloxy)thiophen-2-yl]butanoic acid,
- (6) 2,4-dioxo-4-[5-(3,4-difluorobenzyloxy)thiophen-2-yl]butanoic acid,
- (7) 2,4-dioxo-4-[5-(pyridin-2-ylmethyloxy)thiophen-2-yl]butanoic acid,
- (8) 2,4-dioxo-4-[5-(3-fluorobenzyl)thiophen-2-yl]butanoic acid,
- (9) ethyl 2,4-dioxo-4-[5-(3-fluorobenzyl)thiophen-2-yl]butanoate,
- (10) 2,4-dioxo-4-[5-(4-fluorobenzyl)thiophen-2-yl]butanoic acid,
- (11) 2,4-dioxo-4-[5-(3-chlorobenzyl)thiophen-2-yl]butanoic acid,
- (12) 2,4-dioxo-4-(5-benzylthiophen-2-yl)butanoic acid,
- (13) 2,4-dioxo-4-(5-phenylsulfanylthiophen-2-yl)butanoic acid,
- (14) 2,4-dioxo-4-[5-(3-fluorobenzyl)thiophen-3-yl]butanoic acid,

- (15) 2,4-dioxo-4-[5-(4-fluorobenzyl)thiophen-3-yl]butanoic acid,  
 (16) 2,4-dioxo-4-[5-(3-chlorobenzyl)thiophen-3-yl]butanoic acid,  
 (17) 2,4-dioxo-4-(5-benzylthiophen-3-yl)butanoic acid,  
 (18) 2,4-dioxo-4-(2-phenylsulfanylthiophen-4-yl)butanoic acid,  
 5 (19) 2,4-dioxo-4-[2-(3-fluorobenzyl)thiophen-3-yl]butanoic acid,  
 (20) 2,4-dioxo-4-[2-(4-fluorobenzyl)thiophen-3-yl]butanoic acid,  
 (21) 2,4-dioxo-4-[2-(3-chlorobenzyl)thiophen-3-yl]butanoic acid,  
 (22) 2,4-dioxo-4-[5-(benzyloxy-phenylmethyl)thiophen-2-yl]butanoic acid,  
 10 (23) 2,4-dioxo-4-[5-(phenoxy-phenylmethyl)thiophen-2-yl]butanoic acid,  
 (24) 2,4-dioxo-4-[5-(methoxy-phenylmethyl)thiophen-2-yl]butanoic acid,  
 (25) 2,4-dioxo-4-(5-dibenzylaminothiophen-2-yl)butanoic acid,  
 15 (26) 2,4-dioxo-4-(5-benzylaminothiophen-2-yl)butanoic acid,  
 (27) 2,4-dioxo-4-(5-diallylaminothiophen-2-yl)butanoic acid,  
 (28) 2,4-dioxo-4-(5-di-n-propylaminothiophen-2-yl)butanoic acid,  
 (29) 2,4-dioxo-4-[5-(di-4-fluorobenzylamino)thiophen-2-yl]butanoic acid,  
 20 (30) 2,4-dioxo-4-[5-(N-benzyl-N-methylamino)thiophen-2-yl]butanoic acid,  
 (31) 2,4-dioxo-4-(5-piperidin-1-yl-thiophen-2-yl)butanoic acid,  
 (32) 2,4-dioxo-4-[5-(benzylbenzenesulfonylamino)thiophen-2-yl]butanoic acid,  
 25 (33) 2,4-dioxo-4-(2-dibenzylaminothiazol-5-yl)butanoic acid,  
 (34) 2,4-dioxo-4-(2-benzylaminothiazol-5-yl)butanoic acid,  
 (35) 2,4-dioxo-4-(2-N-benzyl-N-methylaminothiazol-5-yl)butanoic acid,  
 (36) 2,4-dioxo-4-(2-dibenzylaminothiazol-4-yl)butanoic acid,  
 30 and tautomers and pharmaceutically acceptable salts thereof.

14. The compound according to Claim 13 selected from:

- (1) 2,4-dioxo-4-(5-phenethylthiophen-2-yl)butanoic acid,  
 (2) 2,4-dioxo-4-(5-benzyloxythiophen-2-yl)butanoic acid,

- (3) 2,4-dioxo-4-[5-(3-fluorobenzyloxy)thiophen-2-yl]butanoic acid,
- (4) 2,4-dioxo-4-[5-(4-fluorobenzyloxy)thiophen-2-yl]butanoic acid,
- 5 (5) 2,4-dioxo-4-[5-(3,4-difluorobenzyloxy)thiophen-2-yl]butanoic acid,
- (6) 2,4-dioxo-4-[5-(pyridin-2-ylmethyloxy)thiophen-2-yl]butanoic acid,
- (7) 2,4-dioxo-4-[5-(3-fluorobenzyl)thiophen-2-yl]butanoic acid,
- 10 (8) 2,4-dioxo-4-[5-(4-fluorobenzyl)thiophen-2-yl]butanoic acid,
- (9) 2,4-dioxo-4-[5-(3-chlorobenzyl)thiophen-2-yl]butanoic acid,
- (10) 2,4-dioxo-4-(5-benzylthiophen-2-yl)butanoic acid,
- (11) 2,4-dioxo-4-(5-phenylsulfanylthiophen-2-yl)butanoic acid,
- (12) 2,4-dioxo-4-[5-(3-fluorobenzyl)thiophen-3-yl]butanoic acid,
- 15 (13) 2,4-dioxo-4-[5-(4-fluorobenzyl)thiophen-3-yl]butanoic acid,
- (14) 2,4-dioxo-4-[5-(3-chlorobenzyl)thiophen-3-yl]butanoic acid,
- (15) 2,4-dioxo-4-(5-benzylthiophen-3-yl)butanoic acid,
- (16) 2,4-dioxo-4-(2-phenylsulfanylthiophen-4-yl)butanoic acid,
- (17) 2,4-dioxo-4-[2-(3-fluorobenzyl)thiophen-3-yl]butanoic acid,
- 20 (18) 2,4-dioxo-4-[2-(4-fluorobenzyl)thiophen-3-yl]butanoic acid,
- (19) 2,4-dioxo-4-[2-(3-chlorobenzyl)thiophen-3-yl]butanoic acid,
- (20) 2,4-dioxo-4-[5-(benzyloxy-phenylmethyl)thiophen-2-yl]butanoic acid,
- (21) 2,4-dioxo-4-[5-(phenoxy-phenylmethyl)thiophen-2-yl]butanoic acid,
- 25 (22) 2,4-dioxo-4-[5-(methoxy-phenylmethyl)thiophen-2-yl]butanoic acid,
- (23) 2,4-dioxo-4-(5-dibenzylaminothiophen-2-yl)butanoic acid,
- (24) 2,4-dioxo-4-(5-benzylaminothiophen-2-yl)butanoic acid,
- 30 (25) 2,4-dioxo-4-(5-diallylaminothiophen-2-yl)butanoic acid,
- (26) 2,4-dioxo-4-[5-di-n-propylaminothiophen-2-yl]butanoic acid,
- (27) 2,4-dioxo-4-[5-(di-4-fluorobenzylamino)thiophen-2-yl]butanoic acid,
- (28) 2,4-dioxo-4-[5-(N-benzyl-N-methylamino)thiophen-2-yl]butanoic acid,
- 35

- (29) 2,4-dioxo-4-(5-piperidin-1-yl-thiophen-2-yl)butanoic acid,  
(30) 2,4-dioxo-4-[5-(benzylbenzenesulfonylamino)thiophen-2-yl]butanoic acid,  
(31) 2,4-dioxo-4-(2-dibenzylaminothiazol-5-yl)butanoic acid,  
5 (32) 2,4-dioxo-4-(2-benzylaminothiazol-5-yl)butanoic acid,  
(33) 2,4-dioxo-4-(2-N-benzyl-N-methylaminothiazol-5-yl)butanoic acid,  
(34) 2,4-dioxo-4-(2-dibenzylaminothiazol-4-yl)butanoic acid,  
and tautomers and pharmaceutically acceptable salts thereof.

10

15. The compound according to Claim 14 selected from:

- (1) 2,4-dioxo-4-[5-(3-chlorobenzyl)thiophen-2-yl]butanoic acid,  
(2) 2,4-dioxo-4-[5-(3-fluorobenzyl)thiophen-3-yl]butanoic acid,  
(3) 2,4-dioxo-4-[5-(4-fluorobenzyl)thiophen-3-yl]butanoic acid,  
15 (4) 2,4-dioxo-4-[5-(3-chlorobenzyl)thiophen-3-yl]butanoic acid,  
(5) 2,4-dioxo-4-(5-benzylthiophen-3-yl)butanoic acid,  
(6) 2,4-dioxo-4-(2-phenylsulfanylthiophen-4-yl)butanoic acid,  
XII(4)  
(7) 2,4-dioxo-4-[2-(3-chlorobenzyl)thiophen-3-yl]butanoic acid,  
20 (8) 2,4-dioxo-4-[5-(benzyloxy-phenylmethyl)thiophen-2-yl]butanoic acid,  
(9) 2,4-dioxo-4-[5-(phenoxy-phenylmethyl)thiophen-2-yl]butanoic acid,  
(10) 2,4-dioxo-4-(5-dibenzylaminothiophen-2-yl)butanoic acid,  
25 (11) 2,4-dioxo-4-(5-diallylaminothiophen-2-yl)butanoic acid,  
(12) 2,4-dioxo-4-[5-(di-4-fluorobenzylamino)thiophen-2-yl]butanoic acid,  
(13) 2,4-dioxo-4-[5-(N-benzyl-N-methylamino)thiophen-2-yl]butanoic acid,  
30 (14) 2,4-dioxo-4-(2-dibenzylaminothiazol-5-yl)butanoic acid, and  
(15) 2,4-dioxo-4-(2-N-benzyl-N-methylaminothiazol-5-yl)butanoic acid,

and tautomers and pharmaceutically acceptable salts thereof.



16. A pharmaceutical composition useful for inhibiting HIV integrase, comprising an effective amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.

5           17. The pharmaceutical composition of Claim 16, useful for treating infection by HIV, or for treating AIDS or ARC.

10           18. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a therapeutically effective amount of an AIDS treatment agent selected from

- (1) an AIDS antiviral agent,
- (2) an anti-infective agent, and
- (3) an immunomodulator.

15           19. The composition of Claim 18 wherein the antiviral agent is an HIV protease inhibitor.

20           20. The composition of Claim 19 wherein the HIV protease inhibitor is N-(2(R)-hydroxy-1-(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide or a pharmaceutically acceptable salt thereof.

25           21. A pharmaceutical composition made by combining the compound of Claim 1 and a pharmaceutically acceptable carrier.

30           22. A process for making a pharmaceutical composition comprising combining a compound of Claim 1 and a pharmaceutically acceptable carrier.

35           23. A method of inhibiting HIV integrase, comprising the administration to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

24. A method of treating infection by HIV, or of treating AIDS or ARC, comprising the administration to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

5

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/12094

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07D 333/74, 333/56, 333/22, 277/04, 277/18; A61K 31/38, 31/425

US CL :549/43, 57, 70; 548/187, 200; 514/443, 448, 365, 369

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 549/43, 57, 70; 548/187, 200; 514/443, 448, 365, 369

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
cas online structure search

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4,336,397 A (CRAGOE, JR. et al) 22 June 1982, see abstract.	1-24
A	US 4,386,092 A (OE et al) 31 May 1983, see abstract.	1-24
A	US 5,618,830 A (SELNICK et al) 08 April 1997, col.2, lines 20-40.	1-24
X	Database HCAPLUS on STN, AN 1996:13275. LIN, "Substituted pyrazolyl compounds and methods employing these compounds", Chemical Abstracts, Vol. 124, No. 202242, 1996.	1

☒ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

14 JULY 1999

Date of mailing of the international search report

21 OCT 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Rev PCT

Authorized officer

DEBORAH LAMBKIN

JOYCE BRIDGERS  
PARALEGAL SPECIALIST  
CHEMICAL MATRIX

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/12094

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database HCAPLUS on STN, AN 1991:228873. SALEH, R. M. "Use of ethyl 2-thenoylpyruvate in the synthesis of heterocycles and their derivatives", Chemical Abstracts, Vol. 114, No. 228839, 1991.	1
X	Database HCAPLUS on STN, AN 1998:153601. YANBORISOV, T. N. "Synthesis and pharmacological activity of heteroylpyruvic acids and their derivatives", Chemical Abstracts, Vol. 130, No. 153601, 1998.	1